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ABSTRACT 
 
 
This dissertation presents two applications of discrete-event simulation (DES) to 
represent clinical processes: (1) a model to quantify the risk of the maternal obese and 
diabetic intrauterine environment influence on progression to adult obesity and diabetes, 
and (2) a model to evaluate health and economic outcomes of different smoking cessation 
strategies. The first application considers the public health impact of the diabetic and 
obese intrauterine environment‘s effect on the prevalence of diabetes and obesity across 
subsequent generations. We first develop a preliminary DES model to investigate and 
characterize the epidemiology of diabetes during pregnancy and birth outcomes related to 
maternal obesity and diabetes. Using data from the San Antonio Heart Study (SAHS), the 
1980 Census and the NCHS we are able to verify a simplified initial version of our 
model. Our methodology allows us to quantify the impact of maternal disparities between 
different racial/ethnic groups on future health disparities at the generational level and to 
estimate the extent to which intrauterine exposure to diabetes and obesity could be 
driving these health disparities. The populace of interest in this model is women of child-
bearing age. 
The preliminary model is next modified to accommodate data and assumptions 
representing the United States population. We use a mixed-methods approach, 
incorporating both statistical methods and discrete event simulation, to examine trends in 
weight-gain over time among white and black women of child-bearing age in the US 
from 1980 to 2008 using United States Census projections and National Health and 
Nutrition Examination Survey (NHANES) data. We use BMI as a measure of weight 
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adjusted for height.  We establish an underlying population representative of the 
population prior to the onset of the obesity epidemic. Assessing the rate of change in 
body mass index (BMI) of the population prior to the obesity epidemic allows us to make 
―unadjusted‖ projections, assuming that subsequent generations carry the same risk as the 
initial cohort. Unadjusted projections are compared to actual trends in the US population. 
This comparison allows us to quantify the trends in weight-gain over time. This model is 
interesting as a first step in understanding the trans-generational impact of obesity during 
pregnancy at the population level. 
The aim of the second application is to understand the impact of different 
pharmacologic interventions for smoking cessation in achieving long-term abstinence 
from cigarette smoking is an important health and economic issue. We design and 
develop a clinically-based DES model to provide predictive estimates of health and 
economic outcomes associated with different smoking cessation interventions. 
Interventions assessed included nicotine replacement therapy, oral medications 
(bupropion and varenicline), and abstinence without pharmacologic assistance. We 
utilized data from multiple sources to simulate patients‘ actions and associated responses 
to different interventions along with co-morbidities associated with smoking. Outcomes 
of interest included estimates of sustained abstinence from smoking, quality adjusted life 
years, cost of treatment, and additional health-related costs due to long-term effects of 
smoking (lung cancer, chronic obstructive pulmonary disease, stroke, coronary heart 
disease). Understanding the comparative effectiveness and intrinsic value of alternative 
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smoking cessation strategies can improve clinical and patient decision-making and 
subsequent health and economic outcomes at the population level. 
This dissertation contributes to the field of industrial engineering in healthcare. 
US population-level data structures are not always available in the desired format and 
there is not one method for managing the data. The key element is to be able to link the 
mathematical model with the available data. We illustrate various methods (i.e. bootstrap 
techniques, mixed-effects regression, application of probability distributions) for 
extracting information from different types of data (i.e. longitudinal data, cross-sectional 
data, incidence rates) to make population-level predictions. Methods used in cost-
effectiveness evaluations (i.e. incremental cost-effectiveness ratio, bootstrap confidence 
intervals, cost-effectiveness plane) are applied to output measures obtained from the 
simulation to compare alternative smoking cessation strategies to deduce additional 
information. While the estimates resulting from the two models are topic-specific, many 
of the modules created for these studies are generic and can easily be transferred to other 
disease models. It is believed that these two models will aid decision makers in 
recognizing the impact that preventative-care initiatives will have, and to evaluate 
possible alternatives. 
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1 
CHAPTER ONE 
 
INTRODUCTION 
 
 
Disease prevention and control remains a crucial health issue and as costs 
associated with providing health care services spike, patient choices and care become 
more limited. In recent years mathematical modeling of disease dynamics has been used 
to answer health care questions. Integrating analytical techniques into public health 
research, policy, and practice can help lead clinicians and health policy decision makers 
to make recommendations and identify appropriate public health actions to help prevent 
disease, improve patient health, and manage rising health care costs. In this dissertation 
we provide two examples of predictive models for disease management: (1) a model to 
predict the impact of maternal obesity during pregnancy on the prevalence of obesity in 
subsequent generations at the population level across different racial and ethnic groups 
and to identify health disparities among these groups, and (2) a model to provide 
predictive estimates of health and economic outcomes associated with different smoking 
cessation interventions. 
1.1 Background 
Costs of health care have continued to increase for many years. ―Expenditures in 
the United States on health care surpassed $2.3 trillion in 2008, more than three times the 
$714 billion spent in 1990, and over eight times the $253 billion spent in 1980.‖ [Kaiser] 
Health care costs associated with treating chronic diseases in the United States are an 
estimated 75 percent of national health expenditures. [CDC1] Approximately one in two 
adults in the US (133 million individuals) in 2005 had at least one chronic illness [Wu 
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and Green, 2000]. With an increase in the prevalence of chronic illness comes the 
increasing need for understanding of disease and persistent management and treatment of 
disease.  
Mathematical models of disease provide both understanding and prediction of 
disease in a population. Modeling of disease dynamics has been used to choose the most 
effective interventions for preventing and treating disease, understand population 
robustness to disease threats, understand the clinical effectiveness and comparative value 
of different treatment strategies, screen an at-risk population for early signs of a disease, 
understand infectious disease transmission, understand the impact of individual behavior 
and decision making on population-level disease outcomes, predict the future population 
with a given disease, guide resource allocation decisions in health care (e.g., distributing 
funds, allocating organs for transplantation), and influence insurance coverage decisions 
(refer to Section 1.2). Information provided by analytical health care models contributes 
to informed decision-making of public policies impacting human life and health. Small 
increases in the efficiency of the health care system not only lead to improved patient 
outcomes but contribute to tremendous cost savings. 
1.2 Research Aims 
This dissertation presents two applications of discrete-event simulation (DES) to 
estimate long-term epidemiologic and economic consequences of disease processes. 
Thereby, this dissertation is compiled of work from two separate projects which are 
similar in their methodological approach.  
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For application one, we will first create a base simulation model to predict the risk 
of exposure to maternal obesity and diabetes during pregnancy on obesity and diabetes 
prevalence in future generations and to examine trends over time. The model will be 
verified using data for a single cohort. To enable the utilization of cross-sectional 
NHANES data (a nationally representative sample) we will apply bootstrap statistical 
methods and mixed-effects regression models. We then validate our method for modeling 
changes in attributes over time. We begin with an initial cohort and predict prevalence 
rates at baseline. Because we will use cross-sectional data to infer incidence rates, we will 
compare predicted values within an age group to actual values in that age group at 
baseline. That is, we will validate that individuals take on age appropriate characteristics 
according to the baseline cross-sectional values. We model the population prior to the 
onset of the obesity and diabetes epidemic. Using input data from different racial and 
ethnic groups we will quantify health disparities between groups at the population-level 
over time.  
Regarding application two, we will describe the development and verification of a 
simulation to estimate US population-level health and economic outcomes of smoking 
cessation interventions. We will describe how we characterize smoking-related disease 
based on the available data. Analyses to understand the comparative effectiveness and 
intrinsic value of alternative smoking cessation strategies that can improve clinical and 
patient decision-making and subsequent health and economic outcomes at the population-
level will be explained. 
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1.3 Literature Review 
This section discusses health care modeling methodologies and applications 
regarding cost-effectiveness analysis, statistical procedures (logistic regression analysis 
and Bayesian analysis), decision trees, Markov structures (Markov cohort models and 
Markov decision processes), and discrete-event simulation (DES) techniques. Motivation 
behind the DES modeling approach selected for our models is discussed. Since the 
models presented in this dissertation are the first applications of DES to maternal obesity 
and smoking cessation treatment/smoking-related disease risks, DES models applied to 
other diseases are reviewed.  
1.3.1 Cost-effectiveness analysis 
 Cost-effectiveness analysis combines information on monetary costs and health 
benefits (refer to Chapter 5.3) of medical interventions to provide a relative comparison 
of two or more treatment strategies. Health policy-makers use this information to make 
informed decisions about allocating resources. Different modeling methods can be 
applied to perform economic evaluations. Treatment strategies for a broad array of 
diseases including cervical cancer [Mandelblatt et al, 2002], colorectal cancer [McMahon 
et al., 2001], psoriatic arthritis [Bansback et al., 2006], depression [Pyne et al., 2010], 
morbid obesity [Campbell et al., 2010], mental illness [Dixon et al., 2002], prostate 
cancer [Hövels et al., 2009; Ito et al., 2010], HIV [Simpson et al., 2004], and sleep 
apnoea-hypopnea [Sadatsafavi et al., 2009], among many others, have been assessed 
using cost-effectiveness analysis. Chapter 4.1 provides a detailed review of modeling the 
cost-effectiveness of smoking cessation strategies.  
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1.3.2 Statistical procedures 
Chhatwal et al. (2009) developed two logistic regression models to facilitate early 
breast cancer diagnosis where the probability of cancer is the outcome measure in each 
model. These logistic regression models used mammographic features to make breast 
cancer risk predictions which suggest that more accurate decisions may be made using 
the probability of cancer estimated in the two models. However, the results do not 
recommend when the decision should be made to biopsy a particular patient based on 
their risk of breast cancer, and do not consider how patient‘s risks and decisions change 
when individual patient attributes (e.g. age) are taken into account. 
Many authors have been successful at creating prognostic models of disease using 
Bayesian structures to quantify the probability of a disease based on epidemiologic, 
demographic, and clinical information. Bayesian models of disease risk for breast cancer 
[Burnside et al., 2009; Velikova et al., 2009], prostate cancer [Smith et al., 2009], and 
end-stage renal disease [Dimitrov et al., 2003] have been proposed. A predictive model of 
patients with carcinoid was developed by van Gerven et al. (2008) using Bayesian 
inference. Models of survival prediction [Jayasurya et al., 2010] and prediction of local 
failure [Oh et al.; 2011] in lung cancer patients have adopted the Bayesian approach. 
Bayesian networks of gene interactions have been constructed by Armañanzas et al. 
(2008) and Chen et al. (2006).    
Medical data is often hard to accumulate and Bayesian networks are efficient 
when information is lacking in comparison with other modeling methods. Nonetheless, to 
define probabilistic relationships between diseases and symptoms, Bayesian models 
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assume a simple representation of attributes where each problem instance revolves 
around predefined attributes. This is insufficient for medical applications in which patient 
attributes are uncertain, cannot be defined in advance, and change over time. 
Interdependencies among related entities cannot be specified in advance. Because of the 
complex nature of disease, clinical models often require a large state space. In Bayesian 
network modeling the size of the model space is large when few variables are included 
and increases exponentially when variables are added. 
1.3.3  Markov structures 
Previous models of disease most frequently used Markov structures. Sonnenberg 
and Beck (1993) provide an overview of Markov modeling to inform medical decisions. 
Markov models have been used to conceptualize Alzheimer‘s disease [Macdonald and 
Pritchard, 2000], depression [Le Lay et al, 2006], sepsis [Bauerle et al, 2000], human 
papillomavirus (HPV) infection and cervical carcinogenesis [Myers et al, 2000; Dasbach 
et al, 2006], HIV [Simpson et al, 2009], and Type 2 diabetes [The CDC Diabetes Cost-
effectiveness Group, 2002].  
A review of Markov models for coronary heart disease (CHD) interventions is 
discussed in detail in Cooper et al (2006). Decision tree analysis was typically used to 
model acute or short-term CHD interventions and Markov models represented chronic or 
long-term CHD interventions. While the majority of CHD studies evaluated the cost-
effectiveness of treatment strategies, models were also developed to predict the 
prevalence of heart disease on the future population.  
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The Markov approach describes the transition of a homogeneous cohort of 
patients through health states over time. That is, portions of the cohort of patients move 
through the model from one event to another based on the likelihood of moving between 
states. Markov modeling does not represent and evaluate individuals progressing through 
the model. Markov models require mutually exclusive branches or rigidly defined health 
states which must signify every aspect of the disease and transition at fixed cycles. Since 
the individual can only be in one state at a given time, multiple distinct states are required 
to represent all combinations of patient characteristics. The following examples are 
adapted from Caro (2005). At least four states must be defined to represent the 
combination of obese (yes/no) and diabetic (yes/no) using Markov models. In some 
instances it is required that a continuous characteristic (e.g. weight-gain) be modeled as 
discrete (yes or no versus how much weight gained). A large number of states would be 
required to attempt to capture the continuous nature of the weight-gain attribute. Consider 
a change in weight of ±40 pounds which would require almost 20 states to reflect 
changes in weight in five pound increments. This problem is exacerbated if new states are 
generated over time. For example, week one after treatment represents one state, week 
two after treatment represents another state, and so forth. Similarly, the state space 
increases if the course of a disease is influenced by the individual‘s history (e.g. history 
of an event such as a stroke). Markov models may not be suitable in tracking a patient‘s 
disease history properly as they are too limited to consider multiple patient-specific 
demographic and health characteristics in a single model. Restrictions arise with high 
state-space complexity because as the size of the state space increases, the problem 
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becomes harder to solve and can lead intractable solutions. Additionally, Markov chains 
are not compatible when a decision needs to be made at multiple points in time. 
Health care models involving medical treatment decisions have been formulated 
as Markov decision processes (MDPs) to help patients/clinicians design individualized 
treatment strategies which provide optimal clinical outcomes. Schaefer et al (2004) 
provides a good overview of MDP methodology and summarizes the MDP framework in 
terms of medical decision making. Schaefer et al (2004) also summarize several MDP 
applications to medical treatment decisions including the optimal control of an epidemic 
[Lefevre, 1981], a drug infusion plan for dispensing anesthesia [Hu et al., 1996], kidney 
transplantation [Ahn and Hornberger, 1996], mild hereditary spherocytosis treatment 
[Magni et al., 2000], ischemic heart disease (IHD) interventions [Hauskrecht and Fraser, 
2000], breast cancer screening and treatment options [Chhatwal et al, 2010], and liver 
transplantation [Alagoz et al, 2002]. Pneumonia-related sepsis (Kreke et al., 2008), 
ventricular septum defect [Peek, 1999], HIV therapy [Shechter et al., 2008], type 2 
diabetes treatment [Denton et al, 2009], and liver transplantation [Alagoz et al., 2004, 
2007a, 2007b; Sandikci et al., 2008] are also among the studies in this area. 
MDPs encompass similar limitations of standard Markov models but comprise 
additional challenges. Transition probabilities and rewards could vary based on each 
decision made therefore for every possible description of patient health and decision 
enough observations must exist to accurately estimate the transition probabilities. For 
example, the information contained in the state could be a state-action pair for which no 
clinical observations were taken. Therefore, MDPs are more data intensive than other 
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stochastic modeling techniques and the limitations regarding available data may make the 
state space larger and unfavorable. 
1.3.4  Discrete-event simulation 
In recent years, discrete-event simulation (DES) has emerged as the preferred 
method to characterize clinical processes [Caro 2005; Caro et al., 2010; Karnon and 
Brown, 1998]. Le Lay et al. (2006) reviewed Markov models of depression to identify 
methodological weaknesses. A DES of major depression was developed to illustrate the 
benefits of DES in representing disease progression. The performance of a published 
Markov model of HIV was compared to a new DES model of HIV in Simpson et al. 
(2009). The authors summarize the strengths and weaknesses of the Markov approach 
and DES approach in estimating the cost-effectiveness of two antiretroviral HIV 
treatments. Caro et al. (2010) discuss issues with the Markov cohort approach applied to 
treatment for heart disease. Furthermore, Ramwadhdoebe et al. (2009) explain when DES 
is the appropriate modeling technique and how to apply DES to health care modeling 
using pediatric ultrasound screening for hip dysplasia as an example. The authors discuss 
the DES model building process and explain the use of the model for informing health 
care policy makers. 
  DES modeling provides a comprehensive evaluation of patients progressing 
through the model, based upon individual-level demographic and health attributes (e.g. 
age, gender, body-mass index). Patients with differing attributes move from one event to 
another in sequential order while simultaneously taking into account important risk 
factors such as age, gender, disease history and a patient‘s attitude towards treatment, 
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together with any disease-related events (e.g. adverse/acute events such as a stroke or 
heart attack). Probabilities of transitioning between health states can be functions of the 
clinical and demographic measures and can therefore be dependent upon these 
background attributes. For example, gender and age could be assigned independently but 
the patient‘s body mass index (BMI) could depend on the gender and age attributes. 
Individual-based modeling allows different entities to experience different events, and the 
system behavior is a summary of each patient‘s unique clinical history, allowing for 
examination of health and economic outcomes at both the individual and population 
levels. Since DES modeling allows individual attributes to be included in the model, 
compound health states do not have to be defined thus improving the model precision [Le 
Lay et al., 2006; Cooper et al., 2006; Simpson et al., 2009].  
  Entities in a DES model can interact and compete with one another [Shechter et 
al., 2005]. Timing of interactions can be independent of fixed length Markov cycles or 
completely stochastic. Each interaction between individuals can generate a change in the 
state of the system. The path that each participant follows is not necessarily known a 
priori therefore it can be influenced by random local events or changes in the system 
caused by entities moving through the system. The chance for each of the different 
pathways can be assigned by stochastic distributions or fixed probabilities. Since DES 
draws random samples from distributions to variations around the mean, information 
regarding the effect of statistical uncertainty in model input(s) is provided. It is possible 
that a patient re-enters or follows the same pathway in the same run. DES is useful in 
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modeling recursive or random events and is a good approach if one has a very large state 
space to model.  
DES models allow for the creation of lifetime scenarios even though data only 
exists for shorter durations. DES has better long-term predictive validity compared to 
Markov models as DES has the capability to predict more detailed outcomes, thereby 
representing the course of a disease more naturally with few limitations. DES allows 
evaluation of multifaceted stochastic systems and for consideration of probable changes 
in those systems due to different sources of variation. The user can easily perform 
probabilistic sensitivity analysis to study variation in the mean simulation output(s) of a 
model as one or more input parameters are varied. Thus, practitioners can identify the 
most important factors in a large discrete-event simulation. Additionally, the probabilistic 
element of DES allows one to plot the relationships between significant model outputs to 
gain an understanding of how different model predictions correlate.  
DES has been applied to conceptualize HIV/AIDS progression. Bishai et al 
(2007) address allocation decisions for antiretroviral treatment (ART) in developing 
countries by comparing eight treatment strategies including pharmacologic treatment and 
laboratory monitoring. Costs and health outcomes for a cohort of 10,000 HIV-infected 
individuals were obtained. The model ran for 10 years (with the possibility of death) and 
was updated on a 6 month basis. Multiple data sources were used including the 
Multicenter AIDS Study (MACS) and the Women's Interagency HIV Study (WIHS), 
published literature, and parameters from clinical studies to characterize the progression 
of disease prior to ART initiation and after ART initiation. Quantification of the 
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incremental impact and cost-effectiveness of the interventions was presented. A DES 
model of HIV by Linas et al (2009) compared outcomes of two policies to determine 
AIDS Drug Assistance Programs (ADAPs) standards to minimize morbidity, mortality, 
and costs. The progression of HIV-infected patients on and off ART was conceptualized. 
Data from the Massachusetts ADAP in 2004 established a baseline cohort and five-year 
clinical outcomes and program utilization measures were compared. Rauner et al (2005) 
developed a DES describing mother-to-child transmission of HIV in sub-Saharan Africa. 
Two HIV/AIDS interventions were evaluated to identify potential benefits: (1) anti-
retroviral treatment (ART), and/or (2) bottle-feeding strategies. The POST methodology 
was implemented. This model is unique in that mothers and babies were linked (by 
pointers in the entity structure) to one another (i.e. a mother could trace her own mother 
in addition to her offspring). To provide an example of why this is useful, if a mother 
advanced to AIDS while breastfeeding her child, the likelihood of the child developing 
HIV could be altered. A warm-up period of 12 years was required to establish the 
baseline population and model outcomes were evaluated after an additional 12 years. A 
cost-effectiveness analysis was performed to compare scenarios. Results were sensitive to 
assumptions regarding HIV prevalence and baseline infant mortality rate, both dependent 
on local conditions and the efficacy of ART.  
DES models of coronary heart disease (CHD) have been developed for several 
purposes. Babad et al (2002) model prevention strategies for CHD where the baseline 
population consists of healthy individuals (i.e. individuals without CHD). Healthy 
individuals are simulated until they experience their first coronary event. 
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Demographic/clinical attributes included age, sex, systolic blood pressure, total 
cholesterol, and smoking. Adverse CHD events included the onset of stable angina, 
unstable angina, myocardial infarction (MI), and sudden cardiac death. Mortality from 
other cardiovascular disease, stroke, cancer, and all-cause reasons were modeled. Davies 
et al (1993) POST methodology was applied. Input measures were taken from three main 
sources: (1) The Health Survey for England (HSE), (2) The Framingham study, and (3) 
The British Regional Heart Study. This model is referred to in the literature and will be 
further identified as the Prevention model. Cooper et al (2002) model CHD progression, 
prevention, and intervention strategies for a baseline population of sick individuals (i.e. 
individuals with CHD). Individuals in this model experience who an acute coronary event 
(e.g. MI, unstable angina) are followed through treatment until reach stable 
symptomatic/asymptomatic states or death. Patient characteristics include age, sex, 
history of previous events, and the degree of coronary artery vessel disease. Risks in the 
model change following different treatment strategies. The POST modeling approach was 
used to construct the model. The model by Cooper et al (2002) is referred to in the 
literature and will be further identified as the Treatment model. Davies et al (2003) linked 
the models of Babad et al (2002) and Cooper et al (2002) to provide a complete structure 
of prevention and treatment within the population. The purpose of the model was to 
evaluate current and possible future treatment options for the population of England and 
Wales. Cooper et al (2008) extended the Treatment model [Cooper et al, 2002] to 
perform a cost-effectiveness analysis when drugs are given to patients with CHD to help 
prevent adverse coronary events (i.e. myocardial infarction, death).  
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Shechter et al (2005) modeled End-Stage Liver Disease (ESLD) using DES to 
evaluate the effects of possible changes in liver allocation policies in the US. Data from 
the United Network for Organ Sharing (UNOS) and quality-of-life estimates from the 
literature populated the model. Longitudinal data from patient data records of the 
University of Pittsburgh Medical Center was used to assign an individual‘s clinical 
attributes. DES was the chosen methodology to allow individual ESLD patients to 
compete for donor organs. Markov structures cannot generate queues or represent 
individual patients and patient interactions. Disease-specific Cox proportional hazards 
models provided estimates of post-transplant survival (survival estimates for the 
likelihood of death by the patient and organ rejection/loss). Outcomes obtained from the 
simulation were compared with actual UNOS measures to validate the model.  
Davies et al (2004) developed two models of diabetic retinopathy (one for Type 1 
diabetes and another for Type 2 diabetes) to evaluate the ideal setting, screening 
technique, and frequency of screening for early signs of diabetic retinopathy. The model 
was constructed using the POST modeling approach (Davies et al, 1993) and populated 
with data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy to represent 
the untreated progression of disease. Alternative screening and treatment policies of the 
United Kingdom were assessed using cost data from the National Health Service (NHS) 
in 2001. Outcomes indicated differences between policies only regarding the cost-
effectiveness for screening.  
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A DES of gastric cancer using the POST modeling approach was developed and 
used to evaluate the benefits of screening for Helicobacter pylori infection (Davies et al, 
2002). The target population consisted of individuals age 40 and older in the year 2000. 
Sources of input data to represent the general United Kingdom population were multiple 
including published databases and literature. Discounted and undiscounted output 
measures were obtained for costs, morbidity, deaths prevented, and years of life saved. 
Results favored a screening program for Helicobacter pylori infection. Roderick et al 
(2003) used DES modeling to perform a cost-effectiveness analysis in which population 
screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease 
were compared with no screening. The population of England and Wales was represented 
and the POST modeling approach was applied. The authors concluded that Helicobacter 
pylori screening may be cost-effective over a time period greater than 25 years. 
Gestel et al (2010) applied DES to conceptualize the progression of ocular 
hypertension in glaucoma patients and evaluated treatment decisions and effects. Health 
state utility values and costs associated with disease status were modeled. Health and 
economic outcomes were validated and three treatment strategies were compared using 
cost-effectiveness analyses. 
1.4 Dissertation Organization  
 
The remaining chapters of this dissertation are organized as follows. Material for 
the first application is presented in Chapters 2 and 3. In Chapter 2 we focus on the 
development and verification of the obesity and diabetes simulation model. Chapter 3 
presents our approach for handling cross-sectional US population-level data structures 
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and modifies this simulation to accommodate this data. The material for topic two is 
presented in Chapters 4 and 5. The development and verification of the DES model to 
compare therapeutic options for smoking cessation is described in Chapter 4. In Chapter 
5 the base case results of the smoking cessation simulation are discussed and sensitivity 
analysis results are presented. Each chapter provides background information and 
associated literature relevant to the chapter, in addition to discussing conclusions and 
future research opportunities. The dissertation is concluded with Chapter 6 in which we 
summarize the contributions of our research. 
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CHAPTER TWO 
A DISCRETE-EVENT SIMULATION MODEL TO PREDICT LONG-TERM 
IMPACTS OF INTRAUTERINE EFFECTS ON DIABETES AND OBESITY 
PREVALENCE  
 
 
This chapter introduces a discrete-event simulation (DES) model to investigate 
the impact of the maternal diabetic and obese intrauterine environment influence on the 
diabetes and obesity prevalence in subsequent generations. First, we discuss the 
methodology and present a description of the model. We next present and discuss the 
verification of the model and provide an example of the type of results that can be 
obtained from our model. 
2.1 Model Introduction 
 
The goal of this research is to provide quantification of the impact of maternal 
disparities between different racial/ethnic groups at the population level on health 
disparities affecting the populace in the future, where the populace of interest is women 
of child-bearing age. To this end we develop a DES model to predict the affects of 
exposure to maternal obesity and diabetes during fetal life on the prevalence of diabetes 
in subsequent generations to examine trends over long periods of time. The central 
hypothesis is that a mother‘s health influences the health of her offspring which in effect 
characterizes the health of the population, thereby influencing the health of future 
generations. Understanding the impact of fetal exposure to maternal diabetes and obesity 
on future generations will allow estimates to be made regarding the degree to which these 
exposures could be influencing health disparities.  
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The prevalence of obesity and diabetes continues to increase by epidemic 
proportions. A study conducted by the Centers for Disease Control and Prevention (CDC) 
between 1991 and 2001 observed an increase in the incidence of diabetes in the American 
population by 61% and an increase in the incidence of obesity by 74% [CDC2]. An 
analysis performed by the CDC from 2006 to 2008 revealed that the prevalence of 
obesity in African Americans was 51% higher when compared with Caucasians and the 
prevalence of obesity in Hispanics was 21% higher [CDC3].  
As the incidence and prevalence of diabetes continues to escalate, women of 
reproductive age have an increased chance of becoming diabetic while pregnant. Diabetes 
is unique to women because the disease not only affects the mother‘s health but also 
impacts the health of the unborn child [Cowie et al., 2006]. Intrauterine exposure to 
maternal diabetes may contribute to the worldwide diabetes epidemic. Obesity during 
pregnancy predisposes a woman to develop diabetes. Offspring exposed to maternal 
diabetes during gestation may be at higher risk of obesity and diabetes than offspring not 
exposed to the intrauterine diabetic environment, which means this exposure may be 
driving the obesity and diabetes epidemics. Therefore, understanding the 
transgenerational epidemiology of diabetes due to intrauterine programming is important. 
2.2 Model Description and Assumptions 
This section describes the discrete-event simulation (DES) model to investigate 
the impact of intrauterine exposure to diabetes and obesity on the prevalence of diabetes 
and obesity in future generations. The underlying assumptions of the simulation are 
presented.  
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2.2.1 Structure of the simulation 
The simulation model was developed using Arena 13.5 (a product of Rockwell 
Automation Technologies, Inc.) DES software, which allows for fast execution and 
incorporates special purpose features to enhance the modeling of dynamic processes. 
Four modules are included in the simulation:  (1) creation of individuals, (2) disease 
progression, (3) population progression, and (4) statistics. Figure 2.1 provides a 
simplified depiction of how individuals flow through the model. The simulation starts 
with an underlying population and allows for the creation of new individuals each 
successive year. Demographic characteristics are initialized upon entry to the simulation. 
Once the individual has reached childbearing age, health measures [i.e. body mass index 
(BMI), diabetes status] are updated on an annual basis. Individuals meeting specified 
conditions are eligible to reproduce. The offspring appear in the simulation model upon 
reaching childbearing age to feed the birth rates and represent the change in population 
demographics over time. Once pre-determined standards have been realized, the 
individual is removed from the simulation. Output measures are calculated as the 
simulation progresses. Various run conditions and input parameters may be modified 
such as the number of replications, the run length, characteristics of individuals, and the 
number of times an individual can produce offspring. A detailed description of each 
module follows. 
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Figure 2.1: Top-level schematic of flow through the simulation. 
 
2.2.2 Creation of individuals  
The creation module initializes the underlying population and these individuals 
can take on attributes according to the characteristics of the population demographics. A 
 21 
discrete number of individuals enter the simulation according to one arrival which 
represents a single cohort sampled from a chosen population. Upon entry into the 
simulation model, demographic characteristics (i.e. age) and pregnancy attributes (i.e. 
pregnancy status, number of pregnancies) are initialized. The age structure of the 
underlying population was constructed using 1980 US Census data. Since we only 
evaluate women of childbearing age, the age range of individuals in the simulation was 
restricted. All individuals entering the simulation at baseline are females who are not 
pregnant and who are considered to have no previous pregnancies. Baseline BMI is 
determined in the disease progression module. 
 Each individual is also assigned a subset of attributes taking on the characteristics 
of the mother. These attributes include clinical information routinely collected at delivery 
including maternal age, BMI, diabetic status, and obesity status. The maternal attributes 
for the underlying cohort represent the characteristics of a healthy individual. A healthy 
individual is characterized as neither diabetic nor obese. In other words, individuals in the 
starting population are assumed to not have been exposed to diabetes or obesity in utero. 
 Transition probabilities are dependent upon these background attributes. For 
example, age is assigned independently but the patient‘s BMI (used to determine obesity 
status) depends on age and ethnicity. Probabilities of developing diabetes are dependent 
on the mother‘s diabetic status, and the individual‘s obesity status and age. 
2.2.3 Disease progression  
  Each year in the system, individuals travel through the disease progression 
module which consists of two sub-modules: diabetes disease and body mass index (BMI). 
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The diabetes disease sub-module updates a patient‘s diabetic status (diabetic/not 
diabetic). The diabetes disease sub-module can consider different types of diabetes (type 
I and type II diabetes mellitus) according to the available dataset. Once a patient becomes 
diabetic, we assume that the patient remains diabetic until leaving the system. Gestational 
diabetes mellitus (GDM) is taken into consideration in the population progression module 
as a diagnosis of GDM occurs during pregnancy and does not mean that an individual 
had diabetes before conception, or that the individual will have diabetes after giving 
birth.  
  The BMI sub-module assigns starting BMI values in addition to assigning cyclic 
changes in BMI. BMI values are updated annually by age group according to a specified 
distribution. The model can consider BMI with respect to specific population estimates 
for the patient‘s race/ethnic background and gender. A patient‘s BMI can either increase 
or decrease each year in the system. BMI values and annual changes in BMI may be 
restricted based on what is clinically feasible. BMI levels determine obesity status where 
a BMI of 30 kg/m
2
 or greater classifies an individual as obese. 
  Fetal exposure to maternal diabetes was considered present if the mother was 
diagnosed as diabetic before delivery and absent if the mother was not diagnosed as 
diabetic. Transitions from healthy to diabetic are dependent on maternal attributes for 
exposed/not exposed to diabetes in utero, as well as the individual‘s obesity status and 
age. Offspring are not at risk to become sick (diabetic or obese) until they reach 
childbearing age. Upon reaching childbearing age, the offspring are assigned a starting 
BMI value based on the same data used to initialize BMI for the underlying cohort.  
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2.2.4 Population progression  
  The population progression module allows individuals to reproduce. Pregnancies 
were determined based upon probabilities drawn from NCHS natality files [CDC5]. The 
number of pregnancies per individual was restricted to a maximum of eight pregnancies. 
Two conditions define the eligibility to become pregnant. An individual must be of 
childbearing age and the maximum number of allowable pregnancies must not be 
attained. An individual who is not of childbearing age or who has exceeded her 
maximum number of pregnancies continues to cycle through the simulation with a chance 
of getting sick, but with no possibility of getting pregnant. Pregnancy status is adjusted 
with respect to demographic and clinical attributes. The likelihood of getting pregnant is 
evaluated with respect to age; however, pregnancy status can be determined according to 
the individual‘s race/ethnic group. Pregnant women acquire GDM based on age specific 
probabilities and are only considered diabetic for the duration of the pregnancy.  
Table 2.1: Birth rates (births per 1,000 women in specified group), by age. 
Age cohort Birth rate 
18 - 19 73.2 
20 - 24 111.1 
25 - 29 113.8 
30 - 34 61.2 
35 - 39 18.8 
40 - 44 3.5 
 
  We assume that a pregnancy results in one live birth and the offspring is created 
(enters the simulation) the next iteration or simulated year through the system. The health 
of an infant is dependent on the mother‘s health. The offspring‘s clinical and 
demographic attributes are initialized and the offspring takes on the mother‘s 
race/ethnicity. A subset of attributes reflecting the mother‘s attributes is assigned when 
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the offspring enters the simulation. That is, the offspring carries intrauterine environment 
information into the future. Once the offspring is created the mother progresses through 
the model as usual and could become pregnant again in the future. We assume that forty-
eight percent of offspring are female (based on US Census figures), and the male progeny 
are disposed from the system. Female offspring progress through the model and can 
procreate. 
  An accounting sub-module is embedded within the population progression 
module to update the age attribute. Since we are only interested in the prevalence of 
obesity and diabetes in women of childbearing age, the simulation updates the age of 
individuals within the childbearing age limits. When an individual reaches the upper limit 
of childbearing age, the individual is removed from the simulation. Upon leaving the 
simulation, attributes of the individual are output to a file and the individual‘s maternal 
family history can be viewed. 
2.2.5 Statistics  
 
The statistics module updates model outcomes. At any point in time, a cross 
sectional analysis can be made of individuals currently in the cohort to provide a 
prevalence-based measure of the effect of exposure to a disease. The model can 
accumulate population statistics including prevalence rates for obesity, type I and/or type 
II diabetes mellitus, and GDM. These prevalence rates can be viewed annually and 
cumulatively according to different patient attributes (e.g. age group). Additionally, the 
distribution for BMI of individuals in the system can be observed. 
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2.3 Model Verification 
Several measures were taken to verify the model. To ensure conceptual 
verification of the model during the developmental stages, we collaborated with the 
Division of Biostatistics and Epidemiology in the Department of Medicine at the Medical 
University of South Carolina (MUSC). The model was verified by comparing simulated 
measures with data from the 1980 United States Census, the National Center for Health 
Statistics (NCHS), and results from the San Antonio Heart Study (SAHS) [Mitchell et al., 
1991, Stern et al., 1984]. Because we desire an initial population that is representative of 
the population before the inception of the diabetes and obesity epidemic, numbers were 
obtained from the results of the San Antonio Heart Study (SAHS) to provide starting 
inputs for BMI values and type I diabetes mellitus status. Estimates of the prevalence of 
maternal diabetes during pregnancy were abstracted from population-based literature 
[Hunt and Schuller, 2007]. Estimates for the initial cohort represented women ages 18 to 
44 years. 
The SAHS was an 8-year longitudinal study of diabetes and cardiovascular 
disease. The SAHS cohort consists of 5158 men and non-pregnant women between the 
ages of 25 and 64 years. Households from three types of San Antonio neighborhoods 
were randomly sampled including low-income, inner city which is made up of 
approximately 100 percent Mexican Americans, middle-income, and high-income 
districts [Mitchell et al., 1991, Stern et al., 1984]. Data from the SAHS baseline and 
follow-up for females ages 25 to 44 was used as inputs to the model. Since we did not 
have data available for females between the ages of 18 to 24 years, this information was 
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deduced using data from participants ages 25 to 29 years. The sample size of females 
between the ages of 18 and 44 years was assumed to be 358. Data from the SAHS 
provided inputs for two important components of the simulation, the diabetes disease 
sub-module and the obesity disease sub-module.  
SAHS data provided the diabetes incidence rates for the diabetes disease sub-
module. Prevalence of diabetes in the SAHS cohort at baseline over all ages was 1.98 
percent. At baseline, obese individuals are assumed to be 6.6 times more likely to 
develop diabetes than individuals who were not obese. We derive that at baseline 7.38 
percent of obese individuals develop diabetes and 1.09 percent of non-obese individuals 
develop diabetes. Annual probabilities of developing diabetes consider obese individuals 
to be 10.7 times more likely to develop diabetes than individuals who are not obese. 
Using incidence of diabetes over the 7.5 year SAHS period, we derive the annual 
likelihood of diabetes based on obesity status using the cumulative geometric distribution 
(refer to Appendix A for computations).  
Table 2.2: Probability of diabetes mellitus, by age and obesity status. 
Age cohort Not obese Obese 
< 30 0.0009 0.0094 
30 – 34 0.0018 0.0211 
35 – 39 0.0028 0.0329 
40 – 44 0.0026 0.0314 
*BMI of 30 kg/ m
2
 or more is considered obese 
 
SAHS statistics also provided data for the obesity sub-module. Because of the 
small sample size, all distributions for BMI were treated as a truncated normal 
distribution. A lower and upper bound of (µ-1.5σ) and (µ+5σ) respectively was 
established for baseline BMI. Lower and upper bounds for the change in BMI were -σ 
and +2σ, respectively. Numbers from the SAHS demonstrate that 13.7% of women ages 
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25 to 44 are obese at baseline. These numbers were used to initialize starting BMI values 
for the underlying population in the simulation. Yearly change in BMI was based on 
statistics for the change of BMI in the SAHS at baseline and at follow-up 7.5 years later.  
Table 2.3: Input parameters for baseline BMI (kg/m
2
) in the simulation. 
Age cohort Mean St Dev 
< 30 23.4683 5.0056 
30 – 34 23.6806 4.4092 
35 – 39 25.1876 6.6825 
40 – 44 25.2332 5.7084 
 
Table 2.4: Change in BMI (kg/ m
2
) over 7.5 years. 
Age cohort Mean St Dev 
< 30 2.5956 2.8653 
30 – 34 2.4881 3.3886 
35 – 39 2.4119 2.6218 
40 – 44 1.5767 2.1411 
 
Table 2.5: Probability of developing GDM, by age. 
Age cohort 
Annual probability 
of  GDM 
< 30 0.01 
30 – 34 0.03 
35 – 39 0.05 
40 – 44 0.08 
 
2.4 Results 
 In this section we substantiate model performance computationally. We show by 
comparison of system measures and predicted measures that results obtained from the 
model closely represent those obtained from the system. Subsequently, we test different 
assumptions regarding the effects of the obese intrauterine environment on the prevalence 
of diabetes in the population over the long-term. 
2.4.1 Verification results 
 A cohort of 10,000 individuals was simulated over an eight year horizon. The 
childbearing age range was 18 years to 44 years and the age structure was taken from the 
1980 US Census. We measured average BMI, prevalence of obesity, and prevalence of 
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diabetes to verify accurate representation of disease progression. These output variables 
appeared to produce sufficiently small 95% confidence interval (CI) half-widths (HW) 
after 15 replications. The model was implemented using Rockwell‘s Arena Software 
version 13.5.   
First, average BMI and obesity prevalence from the simulation were compared to 
SAHS data. Average BMI measured in the simulation at baseline and follow-up was 24.8 
kg/m
2 
and 26.9 kg/m
2
 (95% CI HW of 0.03 and 0.03, respectively) and data from the 
SAHS gave a mean BMI of 24.5 kg/m
2
 and 26.7 kg/m
2
 at baseline and follow-up, 
respectively. Our model predicts obesity prevalence of 13.8% (95% CI HW of 0.23) at 
baseline compared to 13.7% obese at baseline in the SAHS. Prevalence of obesity in the 
simulation at follow-up measured 24.7% (95% CI HW of 0.27) and 24.3% of the SAHS 
population was obese at follow-up. Next we verified prevalence of diabetes in the 
simulation. Projected diabetes prevalence at baseline was 1.95% (95% CI HW of 0.06) 
compared to 1.98% in the SAHS at baseline. The simulation measured diabetes 
prevalence at 5.86% (95% CI HW of 0.13) and 5.79% of the SAHS population was 
diabetic at follow-up. 
Table 2.6: Verification of performance measures. 
Performance Measure 
Measure 
Baseline  Follow-up 
Simulation SAHS  Simulation SAHS 
Average BMI (kg/m
2
) 24.8 (0.03) 24.5   26.9 (0.03) 26.7  
Obesity prevalence (%) 13.8 (0.22) 13.7   24.2 (0.24) 24.3  
Diabetes prevalence (%) 1.98 (0.08) 1.98   5.86 (0.13) 5.79 
Note: Values in parentheses are 95% CI half-widths 
 
Since the CI half-widths of the simulated performance measures capture the 
SAHS numbers, we are 95% confident that the simulation projections and SAHS 
measures are statistically the same. Projected measures closely correspond to data from 
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the SAHS therefore we believe that our model accurately predicts the outcome of one 
cohort. The performance of the model is assumed to be both a verified implementation of 
the system in addition to a valid representation of the system. We believe that our model 
can realistically forecast other measurements of interest. 
2.4.2 Prevalence of diabetes in future generations 
 Using SAHS data as simulation inputs we tested different assumptions regarding 
the effects of the intrauterine environment on the prevalence of diabetes over the long-
term. A cohort of 10,000 individuals progressed through the simulation for 100 years. 
Output variables were assessed in 5-year intervals. The rate of change in BMI in the 
SAHS population was assumed to remain the same over time. 
First, projections of diabetes prevalence were reported without maternal affects 
(base case). That is, we assume that future generations carry the same risk of disease as 
the underlying population. Next, we projected prevalence of diabetes accounting for 
maternal affects. Maternal affects is characterized as an increased risk of disease because 
of exposure to maternal disease in-utero. We assume an increased risk of diabetes to the 
child if exposed in-utero to maternal obesity to demonstrate the type of estimates that can 
be obtained from our model. Projections can also be made assuming an increased risk of 
diabetes due to intrauterine exposure to maternal diabetes or both maternal obesity and 
diabetes. We focus on the influence of exposure to maternal obesity during fetal life 
because obesity is considered a dominant trait driving America‘s diabetes epidemic 
[CDC4]. 
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We considered different levels for risk of diabetes in individuals exposed to 
maternal disease. Risk factors for diabetes if exposed to maternal obesity during fetal life 
were 1.5-, 2.0-, 2.5-, and 3.0-fold. For example, a relative risk of 1.5 means that an 
individual who was exposed to an obese intrauterine environment has a 50 percent higher 
risk of diabetes than someone not exposed. 
 Regarding base case projections, after 13 years in the simulation individuals less 
than 30 years of age who entered the simulation have matured, and after 18 simulated 
years individuals who entered the simulation at age 34 or younger have aged. After 23 
simulated years all individuals from the underlying population have aged such that 
remaining individuals from the initial cohort are between ages 40 and 44 years. Offspring 
of the underlying population have entered the model and are less than 30 years of age. 
After 30 simulated years none of the base population remains in the simulation, and the 
offspring from this base population are still less than age 30. After 35 simulated years the 
offspring have matured but do not exceed 34 years of age. After 40 simulated years the 
offspring and their offspring have matured but do not exceed 39 years of age. After 45 
simulated years the offspring of the initial population and their offspring exist across all 
age groups and a steady flow of patients continues through the model. 
Prevalence of obesity in the base model without maternal affects does not 
incorporate any additional risk to the offspring if the mother was diabetic while pregnant. 
As the underlying population ages, we can see a steady increase in the prevalence of 
diabetes. Diabetes prevalence steadily increases during the 18 year time period before 
any offspring enter the model. The prevalence of diabetes begins to decline at year 18 and 
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drops to 3.49 percent after 30 years as the young offspring enter the simulation. As the 
children begin to age the prevalence of diabetes climbs to a peak of 11.3 percent after 45 
years. The prevalence of diabetes declines to 8.4 percent after 55 years and then slightly 
increases again to 9.3 percent after 65 years. Diabetes prevalence begins to stabilize after 
65 years reaching a minimum of 8.45 percent and a maximum of 9.56 percent between 
years 65 and 100. We observe an increase in the prevalence of diabetes over time even 
without consideration of maternal affects. 
Figure 2.2 illustrates sensitivity and the expected increase in diabetes prevalence 
for individuals age 18 to 44 years. Considering an increased risk of 1.5 for offspring 
exposed to maternal obesity in-utero, the prevalence of diabetes begins to stabilize after 
65 years at 10.06%. Considering a risk factor of 2 for intrauterine exposure to obesity, the 
prevalence of diabetes begins to stabilize after 65 years at 10.51%. Considering an 
increased risk of 2.5 for offspring exposed to maternal obesity in-utero, the prevalence of 
diabetes begins to stabilize after 65 years at 10.85%. Considering a risk factor of 3 for 
intrauterine exposure to obesity, the diabetes prevalence begins to stabilize after 65 years 
at 12.19%. We observe that intrauterine exposure to maternal obesity leads to an 
intergenerational
 
acceleration in the prevalence of diabetes in the pediatric population. 
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Figure 2.2: Diabetes prevalence (age 18 to 44 years) for increased risk of diabetes due to intrauterine 
exposure to maternal obesity. 
 
In Figures 2.3, 2.4, 2.5, and 2.6 we show trends in the prevalence of diabetes by 
age cohort over time. Observing results across different age groups and across the risk 
factors tested, we notice a more considerable change from each age group at baseline in 
the prevalence of diabetes with respect to the risk factors tested. Among individuals less 
than 30 years of age, predictions were not substantially different from the baseline output. 
The prevalence of diabetes for individuals ages 30 and 34 actually experienced a decrease 
from the prevalence of diabetes at baseline. The prevalence for diabetes of individuals 
age 35 to 39 slightly increased when compared to the base model. We observe the largest 
increase in diabetes prevalence of individuals age 40 to 44. Observing prevalence of 
diabetes by age cohort, we notice a positive correlation between age and diabetes 
prevalence. 
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Figure 2.3: Diabetes prevalence (age 18 to 29 years) for increased risk of diabetes due to intrauterine 
exposure to maternal obesity. 
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Figure 2.4: Diabetes prevalence (age 30 to 34 years) for increased risk of diabetes due to intrauterine 
exposure to maternal obesity. 
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Figure 2.5: Diabetes prevalence (age 35 to 39 years) for increased risk of diabetes due to intrauterine 
exposure to maternal obesity.  
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Figure 2.6: Diabetes prevalence (age 40 to 44 years) for increased risk of diabetes due to intrauterine 
exposure to maternal obesity. 
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2.5 Conclusions 
In conclusion, we developed a simulation model to predict the impact of exposure 
to maternal obesity and diabetes during fetal life on the prevalence of obesity and 
diabetes in subsequent generations and to examine trends over long periods of time. We 
made projections of diabetes prevalence assuming an increased risk of diabetes in 
offspring exposed to maternal obesity in-utero to provide an example of the type of 
projections that can be obtained from our model. Projections could also be made 
assuming an increased risk of diabetes due to intrauterine exposure to maternal diabetes 
or both maternal obesity and diabetes. Studies have assessed the additive effect of fetal 
exposure to both obesity and diabetes but the degree to which adverse effects have on the 
developing fetus has not been quantified [Hunt and Schuller, 2007].  
These three alternatives for taking into account in-utero exposures (increased risk 
of diabetes due to intrauterine exposure to obesity, diabetes, and both obesity and 
diabetes) are considered mutually exclusive cases. Since we are analyzing sensitivity with 
respect to the same risk factors and obesity prevalence is higher than diabetes prevalence 
at baseline, we would expect to notice the largest increase in the prevalence of diabetes 
with consideration to intrauterine exposure to maternal obesity. The underlying 
prevalence of diabetes is smaller at 1.98% diabetic. We would expect to notice less of an 
impact due to the influence of fetal exposure to maternal diabetes than exposure to 
obesity during gestation. Since we are assessing the same risk factors for each case and 
the percentage of the population that is both diabetic and obese is the smallest, we would 
expect to observe a nominal impact over the long-term as a result of exposure to both 
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diabetes and obesity in-utero. We speculate that the risk factors associated with maternal 
exposure to disease in reality are not the same across the three scenarios. 
Verification efforts showed that our model accurately predicts the outcome of one 
cohort. However, extrapolation from the SAHS data is not ideal for three reasons. First, 
the sample size is small, consisting of a maximum and minimum of 575 and 250 samples 
respectively across age categories; second, the SAHS population is not representative of 
the national population and does not include African Americans; and third, obesity and 
diabetes incidence rates in San Antonio were already relatively high in the early eighties 
when the SAHS was initiated. Thus we would like to use baseline data which is large, 
accurate, and captures the population before the prevalence of obesity and diabetes 
increased. 
In this chapter we only look at a specific cohort, however this simulation model 
can easily be modified to accommodate different data structures and assumptions. Future 
simulations representative of the US population will model subsequent generations 
among different racial and ethnic groups and will incorporate information on intrauterine 
exposure to obesity and diabetes in determining an individual‘s adult obesity and diabetes 
status. Chapter 3 aims to extend this simulation to quantify the impact of maternal 
disparities between different racial and ethnic groups at the US population-level on health 
disparities affecting the populace in the future. 
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CHAPTER THREE 
TRENDS IN WEIGHT-GAIN AMONG WHITE AND BLACK WOMEN OF 
CHILDBEARING AGE IN THE UNITED STATES 
 
 
3.1 Introduction 
The prevalence of overweight and obesity among US adults have increased by 
epidemic proportions since 1980. Over the past 30 years the percentage of the US adult 
population that is obese has doubled with approximately 34 percent of adults age 20 years 
and over being obese (BMI ≥30 kg/m2) and an additional 34 percent of adults age 20 
years and over being overweight (30 kg/m
2>BMI ≥25 kg/m2) in 2007-2008 [CDC7]. In 
contrast, the prevalence of obesity was relatively stable between 1960 and 1980; 
however, there is a noted shift in the early 1980s as can be observed by a striking increase 
in the prevalence of obesity between the second and third NHANES (i.e., from 1976-
1980 to 1988-1994) [CDC9, Flegal et al., 1998]. Additional increases in the prevalence of 
obesity occurred in the 1990s [CDC9, Flegal et al., 2002]. The prevalence of obesity 
varies by racial and ethnic group with minority populations having a higher prevalence of 
obesity as well as more severe obesity [Flegal et al., 2010, Ogden et al., 2006].   
 The causes of the obesity epidemic are not completely understood.  Early life 
exposures are emerging as potentially important risk factors for adult diseases including 
obesity and diabetes. The ―fetal origin of disease‖ hypothesis proposes that gestational 
programming may critically influence adult health and disease [Barker, 1995]. As the 
prevalence of obesity increases, its impact on childbearing women and their infants also 
increases; therefore, the obese in-utero environment may be a cause as well as a result of 
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the obesity epidemic. Moreover, trans-generational effects, because of their long term 
implications, may also play a role in the perpetuation of the epidemic. Trans-generational 
effects include genetic information, shared environment and behaviors passed from one 
generation to the next as well as in-utero exposures which may impact gestational 
programming. Moreover, if intrauterine exposure to maternal obesity contributes to 
initiation or perpetuation of the obesity epidemic, then the prevalence of obesity will not 
only increase across all populations, but will disproportionately affect racial/ethnic 
groups with a higher initial prevalence of obesity. Hence, understanding the trans-
generational impact of obesity may be one key to understanding health disparities. 
Because it would take decades to conduct trans-generational studies at the 
population level, we instead use a mixed-methods approach, incorporating both statistical 
methods and discrete-event simulation (DES), to determine the trans-generational impact 
of maternal obesity across multiple racial and ethnic groups at the population level. 
Specifically, we examine trends in weight-gain over time among black and white (non-
Hispanic) women of child-bearing age in the US between 1980 and 2008. This approach 
will enable us to model the trans-generational impact of maternal obesity during 
pregnancy. While substantial increases in the prevalence of overweight and obesity 
among women of reproductive age in the US have occurred over the past several decades, 
the mechanisms underlying the obesity epidemic and its contributing factors are not fully 
understood. In this chapter, we establish an underlying population representative of the 
population prior to the onset of the obesity epidemic and develop a simulation model to 
make projections assuming that subsequent generations carry the same risk as the initial 
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cohort. We compare the simulation projections to actual trends to estimate the increased 
risk in weight-gain over time. Our model uses data obtained from the US Census and the 
National Health and Nutrition Examination Survey (NHANES). We use body mass index 
(BMI in kg/m
2
) as a measure of weight adjusted for height.  
While the prevalence of overweight and obesity over the past two decades has 
been well documented among US adults [Flegal et al., 1998, Flegal et al., 2002, Flegal et 
al., 2010, Ogden et al., 2006], few studies specifically focus on women of childbearing 
age or on disparities between racial/ethnic groups. In one study, Chu et al. (2009) 
estimate the prevalence of prepregnancy obesity in 2004-2005 by analyzing Pregnancy 
Risk Assessment and Monotoring System (PRAMS) data. The work we present here goes 
beyond estimates of past and current trends; with a simulation model we forecast trends 
in weight gain. Several methods exist for conducting projections. Projections can be 
made using statistical models applied to population estimates. For example, Kelly et al. 
(2008) use prevalence data from 2005 and apply it to population projections to estimate 
overweight and obesity prevalence in adults worldwide in 2030.  They make two 
estimates, one assumes that the prevalence of overweight and obesity remained constant; 
the other assumes an increased trend. Our methodology differs from this in that in 
addition to estimating actual trends in weight gain from past data and population 
estimates, we examine ―unadjusted‖ weight-gain in the population over time assuming 
the rate of change in BMI with age of the US population had remained the same as in 
1980.  We do this by using a simulation model. Other methods used to make projections 
include Markov models, such as that used by Honeycutt et al. (2003) to forecast the 
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prevalence of diabetes in the US from 2000 to 2050. We choose to use simulation over a 
Markov model to model BMI trends for several reasons. First, if we wish to capture BMI 
directly (not just prevalence of obesity and overweight), which is dependent on age; the 
state space of such a model would be prohibitively large [BMI is a continuous variable 
while diabetes was modeled as binary variable in Honeycutt et al. (2003)]. It is important 
to be able to capture both BMI and risk by age because risk attributed to diseases of 
interest (e.g. diabetes) vary by BMI and the rate of change of BMI is different between 
age groups. Secondly, the simulation model allows the rate of change in BMI to vary 
over time, and can easily incorporate additional independent variables. This will be 
important in later work, where we attempt to explain the difference in the estimated 
values between actual trends and predicted trends by assigning risk to the children of 
women depending on the BMI level they experienced during pregnancy.    
In this chapter we (1) develop a statistical model to assess the change in BMI as a 
function of age using data obtained through a cross-sectional study design and (2) 
develop and present validation methods for a DES model that examines trends in average 
BMI over generations at the population level. The structure of the chapter is organized as 
follows. In §3.2, we describe the statistical model and present the results of the data 
analysis. In §3.3 we model trends in population weight-gain over time based on the 
statistical analysis. We use a simulation model in §3.4 to model weight-gain trends and 
provide the validation of the simulation model. The chapter is concluded with a 
discussion in §3.5 where future research directions are also presented. 
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3.2 A Model of the Population Prior to the Onset of the Obesity Epidemic  
In this section we describe a method to enable the utilization of cross-sectional 
data to make estimates of change in attributes of individuals over time. We apply our 
method to US population-level National Health and Nutrition Examination Survey 
(NHANES) BMI data. Our method allows us to characterize weight-gain in white and 
black women of childbearing age in the US population prior to 1980 (i.e. before the onset 
of the obesity epidemic). The rate of change in weight-gain prior to 1980 was less than 
the rate of change in weight-gain between 1980 and 2008. Using the rate of change in 
weight-gain before 1980 we model BMI in this population to estimate what the 
population would have looked like if the rate of change in weight-gain had not increased. 
This model will allow us to quantify the increase in weight-gain by comparing the 
simulated population to the actual population over time. 
3.2.1 NHANES data 
The NHANES program, part of the National Center for Health Statistics (NCHS), 
Centers for Disease Control and Prevention involves a sequence of cross-sectional health 
examination surveys beginning in 1960 which concentrate on different population groups 
and health issues.  Each NHANES survey provides a nationally representative sample of 
the US non-institutionalized civilian population obtained using a complex, stratified, 
multistage probability cluster sampling design [CDC8]. Study periods include three 
NHANES surveys (NHANES I, 1971-1974; NHANES II, 1976-1980; and NHANES III, 
1988-1994) and continuous NHANES which began in 1999.  Beginning in 1999 
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NHANES became a continuous surveillance system releasing data in two-year periods 
(1999-2000, 2001-2002, 2003-2004, 2005-2006, and 2007-2008). 
3.2.2 Method for utilization of cross-sectional data  
 We apply mixed-effects regression analysis and bootstrap techniques to make 
inferences about change in trends in BMI over time using cross-sectional data. Here we 
discuss the general steps required to enable the utilization of cross-sectional data to 
estimate change in some dependent variable of interest (in our case BMI) over time. Data 
is divided into cohorts (in our case defined by birth year) based on two key criterion: (1) 
number of available data points of the dependent variable for each possible value of the 
independent variable(s) within the cohort, and (2) fit of the regression model. Every 
cohort should contain enough data points to constitute a representative sample. 
Regression analysis is then performed separately for each cohort. Plots of the best fit 
regression line are created for each cohort and the graphs are superimposed. The form of 
the overlaid plot should approximate a straight line. If the slopes of the superimposed 
lines do not approximate a straight line, cohorts are re-grouped and the process repeats 
(regression analysis and evaluation of superimposed graphs).  
 Linear mixed-effects regression analysis is performed separately for each cohort 
to estimate the rate of change in the value of the dependent variable (e.g.. BMI) that 
results from changes in the independent variable(s) (e.g. age). A bootstrap resampling 
approach is applied to the data for each cohort separately. The size of the bootstrap 
sample is determined based on the total number of data points available for each cohort 
and the bootstrap sample size is the same across all cohorts. Bootstrapped data points are 
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collected over 100 iterations. Bootstrapping provides a sample representative of the 
original sample of uniform sample size across all cohorts. Linear mixed-effects 
regression models are fit to the bootstrapped sample drawn in each of the 100 replications 
thereby providing 100 regression equations. A random effect term accounts for error in 
the bootstrap samples which are not consistent across samples. Obtaining multiple 
equations allowed us to build a probability distribution around the expected value of the 
dependent variable (i.e. BMI) at the intercept, as well as around the rate of change of the 
dependent variable according to the independent variable (i.e. age). 
3.2.3 Statistical analysis of BMI data 
 
In this section, we apply our method to enable the utilization of cross-sectional 
NHANES data to estimate the rate of change in BMI of individuals over time. The 
NHANES I and II studies provide large data sets that capture the population before the 
prevalence of obesity increased [CDC9].  To obtain the BMI data, NHANES collected 
weight and height measurements that were taken through physical examination by trained 
health technicians and were conducted in a mobile examination center using standardized 
measuring techniques and equipment. Body mass index (BMI) was expressed as weight 
in kilograms divided by height in meters squared (kg/m
2
) [CDC8]. 
We use linear mixed-effects regression models to estimate age and birth year 
cohort effects on BMI values of women ages 15 to 44 years in the US measured during 
NHANES I and NHANES II. We assess the relationship between BMI and age to gain 
insights into the change in BMI over time when the data is obtained through a cross-
sectional study design. To avoid cohort effects, data from NHANES I and II surveys were 
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concatenated into one data set. The combined NHANES I and II data set was divided into 
groups of white women and black women based on birth year. Birth year cohorts were 
selected based on the number of available data points from the NHANES I and II surveys 
and based on the fit of various regression models evaluated. In our analysis, at least 30 
BMI data points for each age represented in a birth year cohort were required to provide a 
representative sample. Data for white women was divided into five birth year cohorts: 
1955 to 1959, 1950 to 1954, 1940 to 1949, 1935 to 1939, and 1930 to 1934. Data for 
black women was divided into two birth year cohorts: 1945 to 1959 and 1925 to 1944.  
Regression analysis was performed separately for each birth year cohort to 
estimate the rate of change of BMI values stratified by age using SAS version 9.2 
(sample SAS code for white women born between 1955 and 1959 is provided in 
Appendix C). Sampling weights were included in the regressions to control for unequal 
probabilities of selection in the sample design, lack of responsiveness, and areas under 
covered so that the numbers represented the US population. Analyses were conducted 
using the bootstrap approach to collect repeated random samples from the combined 
NHANES I and II dataset where the sampling was done with replacement. A sample of 
500 BMI data points was collected from the combined NHANES I and II dataset over 
100 iterations. The size of the bootstrap sample was determined based on the number of 
NHANES I and II data points available for each birth year cohort, see parameters in 
Figures 3.1 and 3.2.  Regression analysis was used to fit a model to the bootstrapped BMI 
data points sampled in each of the 100 replications thereby providing 100 regression 
equations. Obtaining multiple equations allowed us to build a probability distribution 
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around the expected mean value of BMI at the intercept, as well as around the rate of 
change of BMI values according to age.  The resulting distributions are shown in Tables 
B.1 and B.2 in the appendix.  
3.2.4 Statistical analysis results 
The table inserts shown in Figures 3.1 and 3.2 provide the age span for each birth 
year cohort, the number of available NHANES I and II data points, the size of the 
bootstrap sample, and the regression equations for white and black women, respectively. 
We note that the age span for different birth year cohorts overlaps in several cases. The 
plots shown in Figures 3.1 and 3.2 display the regression results of BMI versus age 
according to birth year cohort for white and black women, respectively.  The regression 
results for all birth year cohorts are overlaid onto one graph. For white women (Figure 
3.1) we see that the estimated BMI for a particular age does not vary significantly by 
birth year cohort.  The exception occurs over the age span 32 to 37 years. For black 
women on the other hand (Figure 3.2), we see that there is a significant difference in the 
Beta values associated with the two birth year cohorts. How these differences are handled 
is discussed in Section 3.4.4. 
These results provide us with a characterization of weight-gain in the population 
prior to the onset of the obesity epidemic. The next section describes how the regression 
estimates are used to make projections about BMI trends of this population after 1980, if 
their risk for weight-gain had not changed over time.  
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1940-1949 22-37 2825 22.67 0.1518 
1935-1939 32-42 1107 24.12 0.1044 
1930-1934 37-47 1089 24.62 0.1198 
 
 
Figure 3.1: Plot of BMI (kg/m
2
) vs. Age by birth year cohort for white women, regression parameters and 
results shown in table insert. 
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Figure 3.2: Plot of BMI (kg/m
2
) vs. Age by birth year cohort for black women, regression parameters and 
results shown in table insert. 
 
3.3 Unadjusted Population Weight-Gain Projections 
 
In this section we recreate the population using the BMI estimates (stratified by 
age and race/ethnicity) obtained from the regression analysis in which risk of weight-gain 
is the risk in 1980. These ―unadjusted‖ BMI projections reflect trends in this population if 
the rate of change in average BMI between 1980 and 2008 remained the same as it was in 
the 1980s (i.e. if the rate of change in BMI had not increased after 1980). We compare 
differences in BMI from 1980 to 2008 among white and black women of childbearing 
age in the US between NHANES BMI estimates (representing the actual population) and 
our unadjusted weight-gain projections. We expect the NHANES BMI trends for 1980 to 
be statistically the same as the unadjusted projections. We expect NHANES BMI trends 
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after 1980 to be higher than the unadjusted projections. The NHANES estimates 
(representative of the actual population in a given year) are higher because substantial 
increases in the prevalence of overweight and obesity among women of reproductive age 
in the US have occurred since 1980 and continue to occur [CDC7]. Comparison of 
unadjusted projections and actual trends in weight-gain in the US population allow us to 
quantify the increase in incidence rate over time which is not due to change in 
demographics over time. 
3.3.1 Generation of the unadjusted BMI projections 
To make unadjusted projections of this population over time we apply the 
regression estimates of BMI to the US Census age distributions according to 
race/ethnicity using Arena 13.5 software (a product of Rockwell Automation 
Technologies, Inc.). First, the age distribution is assigned using population characteristics 
for white and black women ages 15 to 44 years obtained from the US Census [1980, 
1990, 2000, and 2008 (Census 2008 values are projected based on Census 2000 
numbers)]. Next, age-specific BMI is assigned (independent of birth year cohort) 
according to the normal distribution. Age-specific estimates of BMI from the regression 
analysis provide the mean value of the distribution. The standard deviation is that of the 
actual concatenated NHANES I and II data set. Table B.1 in the appendix provides a 
detailed list of the BMI values (mean and standard deviation) by age and race. Arena was 
run in eight separate scenarios (for white women and black women in 1980, 1990, 2000, 
and 2008) and average BMI was computed for the population age range (15-44) and by 
age groups (15-19, 20-24, 25-29, 30-34, 35-39, and 40-44). 
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In Figure 3.1 we observe overlaps in the different age cohort regression lines for 
white women. When more than one point existed we used the average of the points to 
assign mean BMI. For example, in Figure 3.1 two data points exist for white women age 
17 years, a point estimated from the regression equation for birth year cohort 1955 to 
1959 and a point estimated from the regression equation for birth year cohort 1950 to 
1954. BMI for women age 17 years are taken as the average of estimates for birth year 
cohorts 1955 to 1959 and 1950 to 1954 from the regression analysis.  
  3.3.2 Comparison of average BMI 
Comparison of unadjusted projections and actual trends in weight-gain among 
white and black women of childbearing age in the US population allow us to quantify the 
increase in BMI over time not due to age and race/ethnicity. We compare our unadjusted 
BMI projections to NHANES BMI data representative of the actual population in 1980, 
1990, 2000, and 2008. NHANES estimates are not based on birth year; that is, NHANES 
estimates include all individuals between 15 and 44 years of age in the NHANES 
datasets. The NHANES dataset(s) most closely corresponding to the projected year was 
used as the comparison group. In some instances, more than two years of data were 
needed to have adequate sample sizes for analysis therefore NHANES datasets were 
combined to provide additional data points. Table 3.1 provides a summary of the specific 
NHANES datasets used to obtain BMI values representing the actual population in 1980, 
1990, 2000 and 2008.  
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Table 3.1: Data sources used to obtain numbers representing the actual population. 
Census Year Comparison BMI 
1980 NHANES I and II 
1990 NHANES III 
2000 NHANES 1999-2002 
2008 NHANES 2005-2008 
 
Tables 3.2 and 3.3 show the average unadjusted BMI projections and average 
BMI estimates obtained from the NHANES population by age cohort and year. 
Parentheses define 95 percent confidence interval half-widths. The projections for 1980 
provide a verification of our statistical model. The 95 percent confidence intervals for the 
projected numbers and the actual NHANES numbers overlap (shown in Figure 3.6), 
therefore we conclude that our projections and actual NHANES numbers are statistically 
the same. In other words, the projected population in 1980 (developed from our 
regression model) adequately represents the 1980 population of the NHANES data; 
furthermore, each age cohort is adequately represented in terms of average BMI. 
Furthermore, we can see that beyond 1980, the projected BMI values are less than the 
NHANES values; this is true for all age cohorts and for both black and white women. 
Furthermore, for the overall population (women ages 15-44) the difference in average 
BMI is increasing with time for both black and white women.  
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Table 3.2: Average BMI (kg/m
2
) of white women of childbearing age. 
Age 
Cohorts 
 1980  1990 
 Unadjusted 
Projections 
NHANES I & II 
 Unadjusted 
Projections 
NHANES III 
15 - 19  21.94 (0.08) 21.88 (0.22)  21.94 (0.08) 22.69 (0.56) 
20 - 24  22.67 (0.07) 22.74 (0.22)  22.70 (0.06) 23.59 (0.71) 
25 - 29  23.40 (0.07) 23.33 (0.25)  23.46 (0.07) 24.28 (0.63) 
30 - 34  24.23 (0.08) 24.29 (0.29)  24.15 (0.11) 25.46 (0.72) 
35 - 39  24.61 (0.10) 24.68 (0.31)  24.64 (0.09) 26.59 (0.81) 
40 - 44  25.17 (0.11) 25.13 (0.33)  25.20 (0.12) 26.29 (0.77) 
15 - 44  23.48 (0.03) 23.62 (0.11)  23.75 (0.03) 24.82 (0.28) 
Age 
Cohorts 
 2000  2008 
 Unadjusted 
Projections 
NHANES 1999-
2002 
 Unadjusted 
Projections 
NHANES 2005-
2008 
15 - 19  21.89 (0.08) 23.55 (0.56)  21.90 (0.09) 23.64 (0.60) 
20 - 24  22.74 (0.07) 26.06 (1.09)  22.73 (0.05) 26.22 (1.23) 
25 - 29  23.47 (0.08) 26.69 (1.03)  23.43 (0.08) 27.30 (1.23) 
30 - 34  24.14 (0.10) 26.73 (1.07)  24.14 (0.13) 27.95 (1.06) 
35 - 39  24.63 (0.08) 27.40 (1.18)  24.65 (0.08) 27.92 (1.10) 
40 - 44  25.21 (0.12) 27.71 (1.11)  25.20 (0.12) 28.90 (1.03) 
15 - 44  23.80 (0.04) 25.91 (0.40)  23.69 (0.04) 26.68 (0.42) 
Note: Values in parentheses are 95% CI half-widths. 
 
 
 
Table 3.3: Average BMI (kg/m
2
) of black women of childbearing age. 
Age 
Cohorts 
 1980  1990 
 Unadjusted 
Projections 
NHANES I & II 
 Unadjusted 
Projections 
NHANES III 
15 - 19  22.96 (0.11) 22.81 (0.58)  23.01 (0.10) 24.71 (0.67) 
20 - 24  24.36 (0.09) 24.20 (0.59)  24.38 (0.08) 26.19 (0.68) 
25 - 29  25.87 (0.09) 25.70 (0.71)  25.84 (0.08) 27.24 (0.78) 
30 - 34  27.03 (0.13) 27.13 (0.90)  27.10 (0.13) 29.05 (0.89) 
35 - 39  27.78 (0.16) 28.35 (0.87)  27.77 (0.12) 29.44 (0.81) 
40 - 44  28.69 (0.12) 28.37 (0.82)  28.65 (0.16) 30.61 (0.91) 
15 - 44  25.59 (0.04) 25.80 (0.31)  26.02 (0.05) 27.78 (0.33) 
Age 
Cohorts 
 2000  2008 
 Unadjusted 
Projections 
NHANES 1999-
2002 
 Unadjusted 
Projections 
NHANES 2005-
2008 
15 - 19  23.00 (0.09) 25.67 (0.81)  22.98 (0.09) 26.69 (0.86) 
20 - 24  24.36 (0.08) 29.05 (1.90)  24.38 (0.07) 29.96 (2.03) 
25 - 29  25.88 (0.09) 30.11 (2.02)  25.84 (0.08) 30.66 (1.85) 
30 - 34  27.06 (0.14) 31.29 (1.92)  27.09 (0.15) 31.42 (1.56) 
35 - 39  27.81 (0.11) 30.10 (1.50)  27.78 (0.12) 32.08 (1.85) 
40 - 44  28.65 (0.15) 32.73 (2.00)  28.68 (0.15) 30.75 (1.61) 
15 - 44  26.15 (0.05) 28.44 (0.62)  26.01 (0.05) 29.26 (0.61) 
Note: Values in parentheses are 95% CI half-widths. 
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3.3.1 Comparison of average BMI across age groups 
We are interested in the difference between the average BMI of women based on 
NHANES (which represents the actual population and trends) and the unadjusted BMI 
estimates. Figures 3.4 and 3.5 provide these results by age cohort, for white and black 
women respectively. These figures show the differences in average BMI of the NHANES 
population and the projected population by age cohort in 1990, 2000, and 2008. For 
example, consider the difference in average BMI of white women 20 to 24 years of age in 
1990 (0.88 kg/m
2
). Average BMI computed from the NHANES III dataset represents the 
actual population 20 to 24 years of age in 1990 (23.59 kg/m
2
). Projected average BMI of 
individuals age 20 to 24 years in 1990 is 22.70 kg/m
2
) was obtained by applying our 
regression estimates to the Census 1990 age distribution. The difference between the 
actual NHANES value and the predicted value (i.e., average BMI of individuals age 20 to 
24 computed from the NHANES I and II dataset minus unadjusted average BMI 
projections) for individuals age 20 to 24 years in 1990 is 0.88 kg/m
2
. 
Refer to Figure 3.4 for a discussion regarding the difference in average BMI for 
white women. The difference in average BMI in 1990 is fairly low (i.e., less than 1 
kg/m
2
) in half of the six groups. In 1990, the difference in average BMI for age cohorts 
15 to 19, 20 to 24, and 25 to 29 was comparable ranging from 0.75 kg/m
2
 to 0.88 kg/m
2
. 
The age group with the largest discrepancy between the simulated and NHANES BMI 
values in 1990 were women in age cohort 35 to 39 (1.95 kg/m
2
). In 2000, the difference 
in average BMI across all age cohorts escalated. The difference in average BMI of age 
cohort 15 to 19 was the smallest across all age cohorts (1.66 kg/m
2
). Age cohorts 20 to 24 
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and 25 to 29 hold the largest difference in average BMI in 2000 (3.32 kg/m
2 
and 3.22 
kg/m
2
, respectively). In 2008, we observe a difference in average BMI greater than 3 
kg/m
2
 across all age cohorts except age cohort 15 to 19 (1.73 kg/m
2
). Difference in 
average BMI of age cohorts 15 to 19 and 20 to 24 began to level off between 2000 and 
2008.  
201020001990
4
3
2
1
201020001990
4
3
2
1
201020001990
4
3
2
1
201020001990
4
3
2
1
201020001990
4
3
2
1
201020001990
4
3
2
1
Age 15 to  19
Year
Δ
 B
M
I 
(k
g
/m
^
2
)
Age 20 to  24 Age 25 to  29
Age 30 to  34 Age 35 to  39 Age 40 to  44
1.731.66
0.75
3.48
3.32
0.88
3.87
3.22
0.82
3.80
2.59
1.31
3.27
2.77
1.95
3.71
2.50
1.09
D ifferenc e in  Average BM I (N HAN ES  -  Unadjus ted P rojec tions )  of  W hite W om en
 
Figure 3.3: Difference in average BMI (NHANES-unadjusted projections) by year and age cohort of white 
women. 
 
In contrast to white women, the difference in average BMI of black women across 
the various age cohorts in 1990 is high (Figure 3.5), ranging from 1.40 kg/m
2
 to 1.96 
kg/m
2
 (compared to 0.75 kg/m
2 
to 1.95 kg/m
2
 for white women). Individuals age 40 to 44 
have the largest difference in average BMI (1.96 kg/m
2
) in 1990. Between 1990 and 2000 
the difference in average BMI spikes, particularly among age cohorts 20 to 24 and 25 to 
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29, followed by age cohorts 30 to 34 and 40 to 44. In 2000, the difference in average 
BMI rises to more than 5 kg/m
2
 in one age cohort (20 to 24). The difference in average 
BMI begins to level off between 2000 and 2008 among individuals age 30 to 34. 
Interestingly, between 2000 and 2008 the difference in BMI for black women age 40 to 
44 actually decreases by almost 2 kg/m
2
. This result differs greatly from white women 
age 40 to 44, where the difference in average BMI increased considerably between 2000 
and 2008.  
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Figure 3.4: Difference in average BMI (NHANES-unadjusted projections) by year and age cohort of black 
women. 
 
3.3.2 Comparison in trends over time for black and white women of all ages 
 Next we examine trends in BMI over all ages. In particular, Figure 3.6 compares 
average BMI of women of childbearing age (ages 15 to 44) computed from the NHANES 
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data sets to projected average BMI of women of childbearing age at baseline (1980) and 
for projections in years 1990, 2000, and 2008. NHANES values represent the actual 
population each year while the projections show average BMI of the population if the rate 
of change in BMI had remained stable (i.e. no additional risk since 1980). The 95 percent 
confidence intervals of average BMI for actual NHANES values and unadjusted 
projections are displayed. Average BMI of white and black women computed from the 
NHANES data sets and the projected values are displayed in one panel to show racial 
disparities in average BMI and the rate of change in BMI among white and black women 
of childbearing age. 
The first important result is that the 95 percent confidence intervals about the 
projected numbers and actual NHANES numbers for white and black women age 15 to 
44 years do not overlap in years 1990, 2000, and 2008; therefore the projected numbers 
and actual NHANES numbers are statistically different for years 1990, 2000, and 2008. 
This is true for both white and black women. 
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Figure 3.5: Unadjusted projections vs. NHANES for white and black women of childbearing age. 
 
In 1980 black women of childbearing age had a higher baseline BMI level than 
white women of childbearing age, with actual average BMI of black women at 25.80 
kg/m
2
 compared to actual average BMI of white women at 23.62 kg/m
2
, a difference of 
approximately 2 kg/m
2
 (Figure 3.6). Not only did black women start out with a higher 
baseline BMI value, but the rate of change in average BMI increased faster in black 
women of childbearing age versus white women. Observing actual average BMI of 
individuals age 15 to 44 years (i.e. NHANES), we notice that both white and black 
women experience a steady increase in average BMI between 1980 and 2008. However, 
the rate of change in average BMI of black women increased more rapidly between 1980 
and 1990 compared to the rate of change in average BMI of white women during this 
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time period. A change in average BMI of 1.98 kg/m
2
 in black women compared to 1.2 
kg/m
2
 in white women. Between 1990 and 2000, the rate of change in average BMI of 
white women was higher than the rate of change in average BMI of black women. White 
women experience a change in average BMI of 1.09 kg/m
2
 compared to 0.66 kg/m
2
 in 
black women. The rate of change in average BMI of black women between 2000 and 
2008 again accelerated faster when compared to white women, with a change in average 
of 0.82 kg/m
2
 in black women and 0.77 kg/m
2 
in white women. Overall, the actual change 
in average BMI between 1980 and 2008 was slightly greater among black women of 
childbearing age compared to white women (a change in average BMI of 3.46 kg/m
2
 for 
black women and a change in average BMI of 3.06 kg/m
2
 for white women).  
3.4 Simulation Parameters and Results 
 In this section we use discrete-event simulation (DES) to examine weight-gain 
trends in the US population over time. The simulation model is important because it will 
allow us (in future research) to make projections of weight-gain in this population after 
2008. The simulation model presented in Chapter 2 is modified to make projections 
regarding the rate of change in BMI in the US population if substantial weight-gain had 
not occurred in the 1980s. The reader should refer to Section 2.2 for a complete 
explanation of the simulation structure and assumptions. Our method for validating 
average BMI simulation projections from 1980 to 2008 is described.  
3.4.1 Input data 
Simulation projections were made to assess the ability of the model to forecast 
BMI. The bounds on childbearing age range adapted for the population-level model are 
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age 15 to 44 years. The starting population consisted of 10,000 women ages zero to 44 
years, however, average BMI was only recorded for women of childbearing age (i.e. age 
15 to 44 years). Incorporating these individuals into the simulation at baseline ensures 
that individuals will reach age 15 on an annual basis. NCHS natality files [CDC5] to 
estimate pregnancies and US life tables [CDC6] to estimate mortality allowed us to 
capture changes in age distribution of the US population over time. Model projections 
were made after zero years, 10 years, 20 years, and 28 years, with age structure 
representing the US population in 1980, 1990, 2000, and 2008, respectively. The 
regression analysis provided two key input measures for the BMI sub-module in the 
simulation: (1) age-specific baseline BMI values, and (2) age-specific change in BMI. 
Since there is an overlap in the slopes for certain ages, baseline BMI and updates to BMI 
for women were taken as the average of estimates from the regression analysis (refer to 
Section 3.2 for explanation). The individual‘s baseline BMI was assumed to be normally 
distributed (Table B.1 in the appendix). Table B.2 provides the BMI updates (annual 
change in BMI) used in the simulation model, by age and race; these are also assumed to 
be normally distributed.  
3.4.2 Simulation projections 
 Projections for zero years represent our underlying population of 1980. Baseline 
BMI was used to make projections independent of the individual‘s birth year representing 
the population in 1980. Age-specific baseline BMI was assigned to individuals in the 
starting population and statistics were collected for average BMI with no time elapsing in 
the simulation. To further test the model, projections for average BMI were made over 
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time using age-specific baseline BMI and age-specific BMI updates independent of the 
individual‘s birth year. Average BMI was projected over time to provide estimates for the 
years 1990, 2000, and 2008. The results for all model projections were reported in terms 
of age cohort percentages average BMI according to age cohort (age 15 to 19 years, age 
20 to 24 years, age 25 to 29 years, age 30 to 34 years, age 35 to 39 years, age 40 to 44 
years, and age 15 to 44 years). We implemented common random numbers (CRN) for 
three parameters: (1) baseline age distribution, (2) baseline BMI, and (3) annual change 
in BMI.  
The half-width of average BMI was assessed to determine a sufficient number of 
replications [Law, 2007]. The 95 percent confidence interval half-width was pre-specified 
to be no larger than 0.15 kg/m
2
. Fifteen replications led to a sufficiently small half-width 
confidence interval for the output measure average BMI for all model scenarios. 
Increasing the number of replications did not produce smaller confidence intervals. 
3.4.3 Simulation validation 
We present two methods for validating our simulation model: (1) validation of 
population age distribution, and (2) validation of average BMI estimates. Method one 
compares the percentage age distribution of the US Census to our simulated age structure 
for 1980, 1990, 2000, and 2008. We consider age structure to be an important validation 
criterion because other performance measures (such as BMI) are influenced by the age 
attribute. Age structure results for white women are provided in Table 3.4. 
Referencing Table 3.4, we validate our1980 and 1990 age percentage estimates 
across all age cohorts with 95% confidence interval half-widths in the range of 0.19% to 
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0.36%. In 2000, the difference in mean percentage of women ages 25 to 29 and 30 to 35 
is very low (0.02% and 0.04%, respectively). This is substantial because women of these 
ages are more likely to get pregnant and will therefore have a greater influence on the 
population age structure in future generations. Women ages 15 to 19 and 40 to 44 
maintain the lowest birth rates and will in turn have less affect on the overall population 
structure. Options for improving our simulation projections follow.  
First, some input parameters did not assume standard errors, including the natality 
data and the mortality estimates. We could build a probability distribution around these 
input measures and conduct sensitivity analysis. Second, we could update mortality rates 
every year. Age-adjusted death rates in the US have experienced an overall downward 
trend [CRS, 2006] since 1980. Older individuals have higher risk of death and reducing 
the number of individuals age 40 to 44 will help iron out the distribution and shift the 
percentage towards age 15 to 19. Third, we do not assess variability in the Census 
estimates. Error and undercount of 44.2 million in the Census 2000 count was reported by 
the Accuracy and Coverage Evaluation (A.C.E.) [Census1]. The net undercount for non-
Hispanic whites was 0.6%. An error of 0.51% and 0.10% for age cohorts 15 to 19 and 40 
to 44 respectively in the Census age distribution would validate our simulation. 
For 2008 Census age characteristics we note that the percentages are based on 
Census 2000 numbers. Population projections of the US for 2008 were based on 
assumptions of births, deaths, and immigration [Census2]. Therefore, we have more 
confidence in our projections because our numbers are based on actual natality data 
between 2000 and 2008. 
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Table 3.4: Comparison of the Census and simulation age distributions for white women. 
Age 
Cohorts 
 1980  1990 
 Census (%) Simulation (%)  Census (%) Simulation (%) 
15 - 19  19.38 19.39 (0.36)  14.17 14.12 (0.24) 
20 - 24  20.04 20.00 (0.19)  15.56 15.57 (0.24) 
25 - 29  18.53 18.43 (0.22)  18.00 18.22 (0.30) 
30 - 34  16.96 17.15 (0.27)  18.87 18.77 (0.24) 
35 - 39  13.65 13.65 (0.19)  17.51 17.29 (0.23) 
40 - 44  11.44 11.38 (0.26)  15.88 16.03 (0.25) 
Age 
Cohorts 
 2000  2008 
 Census (%) Simulation (%)  Census (%) Simulation (%) 
15 - 19  15.50 14.70 (0.30)  16.82 16.65 (0.20) 
20 - 24  14.40 14.57 (0.22)  16.57 15.86 (0.31) 
25 - 29  15.00 15.01 (0.27)  16.66 16.26 (0.29) 
30 - 34  16.51 16.55 (0.29)  15.42 15.25 (0.30) 
35 - 39  19.13 19.35 (0.28)  16.83 17.19 (0.25) 
40 - 44  19.46 19.82 (0.26)  17.69 18.79 (0.27) 
Note: Values in parentheses are 95% CI half-widths. 
 
In method two, model validation is achieved when the simulation reproduces 
actual average BMI for the starting cohort (1980 projections) and our hypothetical 
population over time (1990, 2000, and 2008 projections). For all years we consider our 
unadjusted average BMI projections to be the comparison group (representing actual 
population BMI). In Section 3.3 we statistically validated 1980 unadjusted BMI 
projections against average BMI estimates obtained from the NHANES I and II dataset. 
Simulation projections and unadjusted BMI projections (obtained using the regression 
estimates) are compared by age cohort. Average BMI results for white women are 
summarized in Table 3.5.     
Refer to Table 3.5 for a comparison of average BMI unadjusted and simulation 
projections. In 1980 and 1990 we are 99% confident that we capture the true population 
average BMI.  For 2000, simulation projections of average BMI validate for all age 
cohorts except 35 to 39. More importantly average BMI of the overall population (age 15 
to 44 years) validates in comparison to unadjusted BMI projections. Average BMI of the 
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simulated population is driven by the projections of age structure in the simulation. We 
believe that although our 2000 estimates do not capture the actual estimate from the 
Census 2000 for age cohorts 15 to 19 and 40 to 44, if we model random variation in some 
of the input measures (e.g. birth rates, death rates) then our projections will capture the 
true value. In 2008, all age cohorts validate for the performance measure average BMI.  
Table 3.5: Average BMI unadjusted and simulation projections for white women. 
Age 
Cohorts 
 1980  1990 
 Unadjusted 
Projections 
Simulation 
Projections 
 Unadjusted 
Projections 
Simulation 
Projections 
15 - 19  21.94 (0.11) 21.96 (0.07)  21.94 (0.11) 21.84 (0.08) 
20 - 24  22.67 (0.09) 22.70 (0.05)  22.70 (0.08) 22.63 (0.08) 
25 - 29  23.40 (0.09) 23.45 (0.13)  23.46 (0.09) 23.49 (0.09) 
30 - 34  24.23 (0.11) 24.17 (0.11)  24.15 (0.14) 24.19 (0.05) 
35 - 39  24.61 (0.13) 24.70 (0.13)  24.64 (0.12) 24.87 (0.13) 
40 - 44  25.17 (0.14) 25.17 (0.12)  25.20 (0.16) 25.44 (0.12) 
15 - 44  23.48 (0.04) 23.50 (0.05)  23.75 (0.04) 23.81 (0.04) 
Age 
Cohorts 
 2000  2008 
 Unadjusted 
Projections 
Simulation 
Projections 
 Unadjusted 
Projections 
Simulation 
Projections 
15 - 19  21.89 (0.11) 21.85 (0.08)  21.90 (0.12) 21.87 (0.09) 
20 - 24  22.74 (0.09) 22.63 (0.09)  22.73 (0.07) 22.61 (0.08) 
25 - 29  23.47 (0.11) 23.38 (0.09)  23.43 (0.11) 23.42 (0.08) 
30 - 34  24.14 (0.13) 24.14 (0.11)  24.14 (0.17) 24.14 (0.09) 
35 - 39  24.63 (0.11) 24.87 (0.11)  24.65 (0.11) 24.76 (0.09) 
40 - 44  25.21 (0.16) 25.42 (0.07)  25.20 (0.16) 25.40 (0.07) 
15 - 44  23.80 (0.05) 23.86 (0.04)  23.69 (0.05) 23.74 (0.04) 
Note: Values in parentheses are 99% CI half-widths. 
 
3.4.4  Sensitivity analysis  
We performed sensitivity analysis on the BMI updates for white individuals age 
32 to 37 years due to the large difference in the slopes for this age range obtained from 
the regression analysis. Five different scenarios were tested for years 1980, 1990, 2000, 
and 2008. The base case scenario (scenario one), was the average of the slopes for birth 
year cohorts 1940 to 1949, 1935 to 1939, and 1930 to 1934. Scenario two involved 
averaging the points from birth year cohort 1935 to 1939 and 1930 to 1934. Scenario 
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three involved using the slope for birth year cohort 1940 to 1949. BMI updates for 
scenario four involved taking the average of scenarios one and two, and BMI updates for 
scenario five involved taking the average of scenarios one and three. The sensitivity 
analysis showed that average BMI was not sensitive to the BMI updates for individuals 
age 32 to 37 years.  Tables A.3 and A.4 in the appendix show the input parameters (i.e. 
baseline BMI and BMI updates, respectively) used in the sensitivity analysis. Results of 
the sensitivity analysis are provided in Table B.5 in the appendix. 
3.5 Discussion 
The unadjusted projections provide an estimate of the population given that the 
rate of change in average BMI of white and black women of childbearing age in the 
1980s had remained the same between 1980 and 2008. In the unadjusted projections we 
observe similar trends in average BMI for white and black women. In the unadjusted 
projections average BMI of both black and white women of childbearing age increases 
from 1980 to 1990 (a change in average BMI of 0.43 kg/m
2
 for white women and 0.27 
kg/m
2
 for black women) and again slightly from 1990 to 2000 (white women experienced 
a change in BMI of 0.05 kg/m
2
 and black women experienced a change in BMI of 0.13 
kg/m
2
). In the unadjusted projections the biggest change in average BMI occurs between 
1980 and 1990 for both racial groups (0.43 kg/m
2
 for white women and 0.27 kg/m
2
 for 
black women). Average BMI slightly decreases between 2000 and 2008 among both 
white and black women of childbearing age (a change in average BMI of -0.11 kg/m
2
 for 
white women and -0.14 kg/m
2
 for black women).  
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 The 95 percent confidence intervals in Figure 3.6 show a statistical difference in 
average BMI between the actual population and the projected population for years 1990, 
2000, and 2008 for white and black women of childbearing age. The difference in 
average BMI each year is larger for black women compared to white women. For 
example, in 1990 actual average BMI of white women of childbearing age (i.e. obtained 
from the NHANES III data set) is 24.82 kg/m
2
 and predicted average BMI is 23.75 
kg/m
2
, a difference of 1.07 kg/m
2
. The difference in actual average BMI (27.78 kg/m
2
) 
and predicted average BMI (26.02 kg/m
2
) for black women of childbearing age in 1990 is 
1.76 kg/m
2
. The difference in actual average BMI versus projected BMI is greater among 
black women versus white women in 1990, 2000, and 2008. 
In terms of health disparities, the results show two key findings. First, NHANES 
shows that black women not only started out with higher average BMI (25.80 kg/m
2
) as 
compared to white women (23.62 kg/m
2
) in 1980, before the onset of the obesity 
epidemic, but their weight gain between 1980 and 2008 was also higher.  Resulting in an 
average BMI of 29.26 kg/m
2
 (an increase of 3.46 kg/m
2
 over 28 years) for black women 
as compared to 26.68 kg/m
2
 (an increase of 3.06 kg/m
2
 over 28 years) for white women 
over all ages (15-44). The disparity in average BMI between black and white women of 
childbearing increased by 0.4 kg/m
2
 from 1980 to 2008.  Secondly, the unadjusted 
projections show that this difference cannot be solely explained by the weight gain trends 
that were taking place in 1980; that is, the disparity has worsened.  Our unadjusted 
projections predict that if weight gain trends from 1980 had prevailed the disparities 
between these groups would not have increased, rather the difference in BMI between 
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black and white women in 2008 would be 2.32 kg/m
2
, which is not significantly different 
that the disparity seen in 1980. 
The results we provide here are fundamentally different than what is currently 
available in the literature in that we base our unadjusted projections on the population 
previous to the onset of the obesity epidemic. Using cross-sectional data from NHANES I 
and II we determine the change in BMI due to age among white and black women of 
childbearing age. Based on the baseline population, our unadjusted projections show that 
the average BMI among women of childbearing age would be stable from 1980-2008. 
Instead, we find (as do many other studies) that the actual weight gain has increased over 
time. While the reasons for this could be many, understanding the difference between the 
baseline population and the current population is a first and key step to understanding the 
potential causes that could be behind the accelerated weight-gain seen over the past two 
decades, and that will drive longer term projections. 
Lastly, we point out that other studies that make projections on the trends of 
diseases (most of these are done with respect to diabetes) begin with prevalence estimates 
in 2000 or later.  At this point the obesity (and also diabetes) epidemics had already taken 
place; resulting in very high estimates. Wang et al. (2008) use NHANES 1976-1980 to 
2003-2004 to calculate the average annual increase in the prevalence of obesity and 
overweight and apply this using a linear regression model to make projections through 
2030, resulting in an estimated 87% of all adult women being overweight or obese. Other 
examples of projection studies which begin with data after the onset of the ―diabesity‖ 
epidemic include: diabetes projections for the US population through 2031 [Mainous et 
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al., 2007] and through 2050 [Boyle et al., 2001], obesity projections for South Australia 
through 2013 [Dal Grande et al., 2005], and global diabetes projections through 2030 
[King et al., 1998].  In this paper we considered the weight gain trends associated with 
NHANES I and II (1971-1974 and 1976-1980) and find that these trends would have 
resulted in stable average BMI levels compared to actual BMI trends over time. 
As discussed in Section 3.4.3 (Tables 3.4 and 3.5), our simulation projections at 
baseline, 1990, and 2008 validate statistically for two measures (age structure and 
average BMI). In 2000, we validate average BMI across all age cohorts except 35 to 39. 
We believe that by incorporating random variation in birth and death estimates and 
accounting for Census errors, we can validate our 2000 estimates for age cohort 35 to 39. 
We are confident in our simulation projections for one generation of one cohort (white 
women of childbearing age). However, we acknowledge that our simulation has 
limitations.  
 In terms of limitations, first, a key limitation is that the Census 2000 data set 
contains an enormous amount of errors (many more than the Census 1990) [U.S. Census 
Monitoring Board, 2001]. This not only affects simulation projections (in terms of 
simulation validation), but also impacts the unadjusted BMI projections over time. Next, 
pregnancy probabilities are not subject to random variation. Registered births occurring 
in the US are not 100% accurate and may be influenced by non-sampling errors (i.e. the 
mother‘s age or race may be mistakenly documented) [CDC10]. Similarly, US life table 
errors (i.e. errors in death rates) such as mistakes in recording age on the death certificate 
may distort age-adjusted death counts. Under-registration of deaths is not assumed to be 
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significant for reasons including burial permit requests, acquirement of insurance 
benefits, and estate settlements. Last, reasons other than births or deaths shape the 
population (e.g. immigration) [Bell and Miller, 2005].  
We are currently making attempts to address the limitations of our data sources. 
Sensitivity analysis will assess how robust the simulation is to these input measures. With 
the release of Census 2010 estimates our projections will be updated and age 
characteristics validated against actual Census estimates (rather than Census projections 
of 2008). 
Future research will be conducted to test different models for attributing increased 
risk in weight-gain over time. Various epidemiologic models for increased risk will be 
evaluated to determine which model projections most closely resemble the actual data of 
the US population. The results will be used to predict effects due to the obese intrauterine 
environment. Once the risk factor is established, projections will be made regarding 
weight-gain and the prevalence of obesity over a longer time period (e.g. 100 years). 
These projections will demonstrate the extent to which these affects may be exacerbated 
over time. We seek to quantify the impact of intrauterine exposure to maternal obesity 
across multiple generations in different race/ethnicity groups at the population level 
thereby allowing estimations to be made regarding the extent to which intrauterine 
programming could be influencing health disparities. This research will aid decision 
makers in recognizing the impact of preventative-care initiatives as well as in the 
evaluation of possible alternatives. 
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CHAPTER FOUR 
 
A DISCRETE-EVENT SIMULATION MODEL TO ESTIMATE HEALTH AND 
ECONOMIC OUTCOMES OF SMOKING CESSATION TREATMENTS 
 
 
This chapter focuses on the development and verification of a DES model to 
estimate health and economic outcomes associated with smoking cessation interventions.  
4.1 Model Introduction 
  According to the US Surgeon General, active cigarette smoking remains a major 
public health problem, despite numerous health warnings, FDA regulation, highly 
publicized litigation efforts against major tobacco companies, and a bevy of accumulated 
epidemiologic evidence chronicling the health risks of smoking [US Department of 
Health and Human Services, 2004]. Countless studies have demonstrated that ―smoking 
is the single greatest cause of avoidable morbidity and mortality in the United States‖ 
[US Department of Health and Human Services, 2004]. However, smoking prevalence 
remains quite high, and despite the fact that 70% of smokers want to quit, long-term 
smokers have considerable difficulty breaking the habit and overcoming addiction to 
nicotine [CDC11].   
Multiple smoking cessation therapies and interventions have been developed 
since the early 1960s to aid smokers who desire to quit; however, more than 46 million 
adults in the United States continue to smoke cigarettes and even with pharmacologic 
intervention, recidivism remains extremely high [CDC12].  Smokers who desire to quit 
often try numerous unsuccessful pharmacotherapies, which may be costly and generally 
ineffective, resulting in economic hardship and feelings of failure or guilt [Ranney et al., 
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2006].  Considering the significant health and economic burden of smoking and the 
unavailability of a tried and true ―magic bullet‖ for smoking cessation, comparative 
effectiveness studies are needed to compare different smoking cessation options and 
corresponding outcomes.   
Although the effectiveness of smoking cessation therapies has been low, smoking 
cessation, when successful, has been shown to be highly cost-effective. Studies have 
compared placebo to different pharmacologic interventions for smoking cessation 
[Jackson et al., 2007; Neilson and Fiore, 2000]. Studies have compared the nicotine patch 
to smoking-cessation counseling [McGhan and Smith, 1996; Fiscella and Franks, 1996; 
Cromwell et al., 1997] and nicotine gum to smoking-cessation counseling [Cromwell et 
al., 1997]. Gilbert et al. (2004) included five pharmacological treatments including 
nicotine gum, patch, nasal spray, inhaler and bupropion in which the control group 
received smoking-cessation counseling and the treatment cohort was given counseling in 
addition to pharmacological treatment. Howard et al. (2008) compared varenicline, 
bupropion, nicotine replacement therapy, and unaided smoking cessation where the main 
objective of the study was to assess the cost-effectiveness of varenicline. 
Cost-benefit studies of smoking cessation therapies that require decision making 
under uncertainty have employed decision tree analysis [Fiscella and Franks, 1996; 
McGhan and Smith, 1996; Nielsen and Fiore, 2000; Jackson et al., 2007] and Markov 
structures [Orme et al., 2001 (in Reifsnider, 2011); Gilbert et al., 2004; Gilbert et al., 
2006 (in Reifsnider, 2011); Howard et al., 2008] to provide a simplified description of a 
complicated clinical problem which aids decision makers in understanding the risks and 
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benefits of various clinical options. To our knowledge, discrete-event simulation (DES) 
has not been employed to compare therapeutic options for smoking cessation and related 
health outcomes. Because individuals have varying levels of nicotine dependence and 
smoking intensity, and because of significant heterogeneity in treatment response, we 
believe the DES approach is a potentially more meaningful way to conceptualize the 
problem of smoking cessation. 
The remaining chapter is organized as follows. In §5.2, a description of the data 
and assumptions of the simulation is provided. In §5.3, measures of health and economic 
evaluation are described and the simulation verification is described in §5.4. The chapter 
is concluded with §5.5, in which we discuss limitations of the model and future research 
directions.  
4.2  Model Assumptions and Data 
4.2.1 Simulation structure 
We developed a DES model using Arena 13.5 software. The simulation consists 
of four main modules: creation of smokers, smoking cessation treatment, disease 
progression, and accounting (Figure 5.1). The accounting sub-module periodically 
updates patient attributes and population statistics. In terms of the progression of the 
model, first, individuals are created and all individuals are assumed to be smokers. Next, 
the smoker begins treatment and the model evaluates, according to trial-based efficacy 
evidence, whether or not the treatment was successful. If treatment is successfully 
completed, then the patient enters the non-smoker state; otherwise, the patient remains a 
smoker with no additional attempts at treatment. A periodic update of patient disease 
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progression, aggregate quality adjusted life-years (QALY), health utilities, costs, age, 
mortality, and statistical accumulation occurs annually regardless of the patient‘s 
smoking status. A detailed description of the operations of each sub-module follows. 
 
Figure 4.1: High-level schematic of simulation flow. 
 
4.2.2 Creation of smokers 
The creation module creates smokers and allows the administrator to input 
background demographic and clinical information of the underlying population. A 
discrete number of patients enter the system representing a single cohort sampled from a 
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chosen population. The initial cohort consists of 10,000 individuals made up of males and 
females ages 18 to 70 years, assigned according to 2008 US Census population tables 
[Census2] and US smoking prevalence estimates taken from the 2008 National Health 
Interview Survey (NHIS) [NCHS, Table 4.1]. Refer to Appendix table D.1 for the 
calculated distribution of smokers. No additional entities enter the simulation; however, 
individuals may exit the model due to death. Demographic and clinical attributes are 
assigned to each individual in the simulation at baseline including gender, age, and 
quality of life (refer to Section 4.3.1). Quality of life numbers were drawn from the 
literature [Fiscella and Franks, 1996; Stewart et al, 2009 (in Reifsnider, 2011)] and are 
assigned based on individual demographic attributes. For example, gender and age are 
assigned independently but utilities or quality of life associated with certain health states 
depend upon the gender and age attributes. Probabilities of transitioning between health 
states are also dependent upon these background attributes. All patients enter the model 
as smokers and are considered ―healthy‖ at baseline. A healthy patient is characterized as 
a smoker with no serious smoking-related co-morbidities of interest [i.e., lung cancer, 
chronic obstructive pulmonary disease (COPD), stroke, coronary heart disease (CHD)]. 
Table 4.1: Smoking prevalence among adults in the US. 
Age Group Male Female 
18 - 44 0.254 0.203 
45 - 64 0.246 0.205 
65+ 0.106 0.082 
 
4.2.3 Smoking cessation treatment 
Smoking cessation alternatives considered in this model include nicotine 
replacement treatment (NRT) interventions, bupropion, varenicline, and non-
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pharmacologic-assisted cessation. The four NRT products considered in this model 
(patch, inhalator, gum, and nasal spray) are known to have different costs, adherence, and 
outcomes; hence, average statistics across the four NRT products are input into the 
simulation to represent the NRT treatment option. We run the simulation in five 
scenarios, one scenario for each of the four strategies (NRT, bupropion, varenicline, and 
non-pharmacologic-assisted) and one for no treatment. 
Upon entry into the simulation, 100 percent of smokers make one attempt at 
treatment. Duration of active treatment is 12 weeks for all interventions of interest 
[AMA, 2000] and individuals are assumed to adhere to treatment for the full duration. 
Intervention-specific efficacy rates are applied at the end of year one at which time 
individuals either successfully quit smoking or remain smokers. Reported efficacy rates 
for smoking cessation are highly variable, therefore we performed a meta-analysis of the 
efficacy of smoking cessation strategies to obtain an estimate of the summary effect size 
across studies. A review of the medical literature identified 6 studies for NRT, 6 studies 
for bupropion, 5 studies for varenicline, and 4 studies for non-pharmacologic-assisted 
(Table 4.2). Results across studies per strategy were combined to provide a single pooled 
result quantifying how much each intervention is beneficial. The mid-point value was 
considered our baseline probability of treatment success.  
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Table 4.2: Efficacy rates (defined as treatment-specific, CO
2
-verified, continuous abstinence rate over a 
one-year time period, i.e. during trial follow-up). 
Cessation alternative Proportion Abstinent Reference* 
NRT 0.13 (0.06-0.20) 
Aubin et al, 2008; Bohadana et al, 2000; Jorenby et al, 
1999; Nielson and Fiore, 2000; Silagy et al,  2002; 
Raw, McNeill, and West, 1998 
Bupropion 0.225 (0.15-0.30) 
Jorenby et al, 2006; Fossati et al, 2007; Jorenby et al, 
1999; Nides et al, 2008; Silagy et al, 2002; Gonzales 
et al, 2006 
Varenicline 0.215 (0.18-0.25) 
Niaura et al, 2008; Garrison et al, 2008; Rigotti et al, 
2010; Gonzales et al, 2006; Nides et al, 2008 
Non-pharmacologic-
assisted 
0.05 (0.03-0.07) 
Hughes et al, 2004; Raw, McNeill, and West, 1998; 
Foulds et al, 2004; Fiore, 2000 
NRT = Nicotine Replacement Therapy 
* Refer to Reifsnider (2011). 
 
Successful quitters are referred to as former smokers and are at risk of relapse 
(refer to Section 4.2.5 for more explanation) as they move through the disease 
progression and accounting modules each year. Individuals who did not successfully quit 
smoking loop through the disease progression and accounting modules each year until 
death. 
4.2.4 Disease progression 
Although smoking is a risk factor for numerous non-communicable diseases, we 
chose to focus on lung cancer, chronic obstructive pulmonary disease (COPD), stroke, 
and coronary heart disease (CHD), for two reasons. First, these four diseases represent 
significant epidemiologic and economic burdens to American society [US DHHS, 2004] 
and second, good data exist on the probabilities and outcomes for these disease states in a 
smoking population. Diseases are either present/absent with the possibility of acute 
exacerbation or improvements in condition. Individuals may develop one or more 
smoking-related condition. Estimates of lung cancer, COPD, stroke, and CHD were 
determined by the literature and considered to be dependent upon demographic attributes 
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(age and gender) and the individual‘s smoking status - current smoker or former smoker. 
The disease progression module updates the individual‘s health state annually. The health 
state not only takes account of diagnoses of chronic conditions (and corresponding health 
utilities), but also considers incident complications associated with each co-morbidity, 
such as a COPD exacerbation. 
An individual may develop different levels of COPD (mild, moderate, or severe). 
In the absence of good data about COPD transitions between mild, moderate, and severe 
disease, we assumed that people diagnosed with COPD were diagnosed with mild, 
moderate, and severe disease according to proportions in the literature and that they 
remained in those ―states‖ until death. Baseline utility values are assigned to individuals 
who have COPD (Table 4.9 of Section 4.3.1). Individuals living with COPD are at risk of 
COPD exacerbations (minor or major). Refer to Table 5.3 for estimates of COPD.        
Annual incidence of COPD exacerbation is modeled for each COPD level by 
applying the binomial probability distribution. For example, the exacerbation rate per 
annum for mild disease of 0.79 is converted to an annual probability of 0.5462 [1-e
(0.79)
]. 
We assume a maximum of 4 possible COPD exacerbations annually. Since the expected 
value, E(x), of a binomial distributed random variable is the product of the number of 
trials [(n); 4] and the proportion of success [(p), COPD exacerbation] we compute the 
likelihood of independent COPD exacerbations to be 0.1366. The probability table is 
given in Table D.2 of the Appendix. Next, we determine how many major exacerbations 
occurred using the binomial distribution formula and given the annual number of COPD 
exacerbations and the percentage of minor exacerbations (refer to Appendix Table D.3 
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for computed probabilities). COPD utility values are weighted based on the number and 
type of COPD exacerbations. COPD exacerbations lower the baseline COPD utility 
values for a period of 3 months. 
Table 4.3: Lifetime probability of developing COPD, by gender and smoking status. 
Risk of developing COPD
a
 Cumulative/lifetime probability of COPD** 
      Current smoker  
            Male 0.32 
            Female 0.32 
      Former smoker/non-smoker*    
            Male 0.13 (0.12-0.14) 
            Female 0.13 (0.12-0.14) 
Severity of COPD
b
 Proportion in each severity category 
      Mild disease  70.34% (68-73%) 
      Moderate disease 19.33% (19-20%) 
      Severe disease 10.33% (8-13%) 
COPD exacerbation
c
 Exacerbation frequency (per annum) 
      Mild disease  0.79 
      Moderate disease 1.22 
      Severe disease 1.47 
Minor exacerbation
c
  
      Mild disease 94% 
      Moderate disease 93% 
      Severe disease 90% 
COPD = chronic obstructive pulmonary disease 
*We assume a former smoker carries the same risk as a non-smoker 
** Lifetime probability calculated by converting lifetime rate to annual probability using sex-
specific life expectancy tables for smokers at 50 years; former smokers group denominator 
calculated using the average LE between current smokers and general population 
(a) Reference is Pelkonen et al. (2008), (b) Reference is Wilson, Devine, and So (2000), (c) 
Reference is Spencer et al. (2005) [(refer to Reifsnider (2011)] 
 
 Individuals are at risk of multiple stroke exacerbations over their lifetime. 
Estimates of stroke are provided in Table 4.4. Stroke utility values are weighted to reflect 
the two month period following the first stroke event. Subsequent strokes result in a 
permanent decrement in the stroke utility value. Utility values for stroke are shown in 
Table 4.9. 
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Table 4.4: Age-standardized rate of stroke per 100,000 person-years, by gender and smoking status. 
 Current smoker Former smoker* 
      Male 656.6 496.4 
      Female 565.6 506.7 
* We assume a former smoker carries the same risk as a 
non-smoker 
 
 
 
 
 
 
 
 
Table 4.5: Risk of lung cancer, by smoking status.* 
Current smoker
**
  Incidence rate 
      Age < 55 years***  0.0000 
      Age 55-64 years  6.0000 
      Age 65-74 years  7.5000 
      Age 75-84 years  8.1667 
      Age > 84 years  8.1667 
* Incidence rate of lung cancer among nonsmokers, 
in person years (100,000) 
**Current smoker = averaged 1pack/day and 2 
packs/day for 25 years, 40 years, and 50 years 
 ***We assume that individuals less than 55 years of 
age do not develop lung cancer 
Former smoker: relative risk = 10 
Reference: in Reifsnider (2011) 
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Table 4.6: Age-specific, ten-year rate of CHD, by gender, age, and smoking status. 
Current smoker                           Incidence rate Former smoker*                     Incidence rate 
      Male        Male  
            Age < 30 years** 0.0000             Age < 30 years** 0.0000 
            Age 30-34 years 0.0336             Age 30-34 years 0.0200 
            Age 35-39 years 0.0504             Age 35-39 years 0.0300 
            Age 40-44 years 0.0672             Age 40-44 years 0.0400 
            Age 45-49 years 0.0672             Age 45-49 years 0.0400 
            Age 50-54 years 0.1008             Age 50-54 years 0.0600 
            Age 55-59 years 0.1176             Age 55-59 years 0.0700 
            Age 60-64 years 0.1512             Age 60-64 years 0.0900 
            Age 65-69 years 0.1848             Age 65-69 years 0.1100 
            Age 70-74 years 0.2352             Age 70 years 0.1400 
            Age > 74 years** 0.2352             Age > 74 years** 0.1400 
      Female        Female  
            Age < 30 years** 0.0000             Age < 30 years** 0.0000 
            Age 30-34 years 0.0074             Age 30-34 years 0.0050 
            Age 35-39 years 0.0147             Age 35-39 years 0.0100 
            Age 40-44 years 0.0294             Age 40-44 years 0.0200 
            Age 45-49 years 0.0441             Age 45-49 years 0.0300 
            Age 50-54 years 0.0735             Age 50-54 years 0.0500 
            Age 55-59 years 0.1029             Age 55-59 years 0.0700 
            Age 60-64 years 0.1176             Age 60-64 years 0.0800 
            Age 65-69 years 0.1176             Age 65-69 years 0.0800 
            Age 70-74 years 0.1176             Age 70-74 years 0.0800 
            Age > 74 years** 0.1176             Age > 74 years** 0.0800 
CHD = coronary heart disease 
* We assume a former smoker carries the same risk as a non-smoker 
**We assume that individuals less than 30 years of age do not develop  CHD 
***We assume the risk for CHD in the oldest age group is equal to the next closest age group 
Reference: in Reifsnider (2011) 
 
Improvements in condition are taken into account by allowing the health state 
utility to be modified for post-exacerbation improvements over time, which is relevant 
for acute events such as stroke and COPD exacerbations. For example, patients who have 
suffered a stroke are considered to have a history of stroke, which is an improvement 
over the actual stroke event itself, and patients who have suffered more than one stroke 
are considered to have a history of multiple strokes. An individual who experiences a 
stroke has a corresponding utility of 0.425 for the event itself (in this case, we assume 
quality of life is seriously affected for two months) [Wolf et al., 1992 (in Reifsnider, 
2011)].  After two months, the individual‘s condition improves but still has an average 
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utility considerably worse than perfect health, 0.725, reflecting stroke-related disability 
[Howard et al., 2008]. If the same person has an additional stroke, the utility drops 
substantially because we assume that multiple strokes lead to significant 
disability/morbidity. 
Individuals are at risk for disease-specific mortality per annum. We model two 
causes of death - disease-specific mortality and all-cause mortality - which allows both 
deaths from smoking-related diseases of interest and death from natural causes to be 
taken into account. Deaths due to lung cancer, COPD, stroke, and CHD complications are 
accrued within the disease progression module. Mortality from all causes is determined in 
the accounting module.  
Case fatality rates are used to estimate disease-specific risk of mortality (Table 
4.7). Case fatality rates are specific to those people who have already been diagnosed 
with a disease; that is the proportion of individuals with a disease who die from the 
disease during a given time period. Information is not available for smoking status-
adjusted case fatality rates. Since the incidence rates for disease have been adjusted by 
smoking status, there is no reason to think that once diagnosed with the disease of 
interest, smokers should have differential risk of death than non-smokers. So, once 
individuals have the disease of interest, we assume their prognosis is similar.  
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Table 4.7: Case fatality rates over the time period of interest. 
Co-morbidity Case fatality rate Reference 
CHD   
      At 1 year 44.5% MacIntyre et al, 2000 
      At 5 years 76.5%  
      At 10 years 87.6%  
Stroke (exacerbation)   
      1 year overall 35% (32-38%) Nieuwkamp et al, 2009; Feigin et al, 2003 
Lung Cancer   
      At 5 years 85% Parkin et al, 2002 
COPD   
      After at 1+ major exacerbation  15.6% Hoogendoorn et al, 2010 
CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease 
 
We assume the case fatality rate of CHD and lung cancer to increase linearly over 
time. COPD-related death is possible if at least one major exacerbation occurred, 
regardless of the level of disease (mild, moderate, or severe). A case fatality rate of 35 
percent is assumed if an individual experiences at least one stroke annually. 
4.2.5 Accounting module 
The accounting module serves several purposes. First, patient attributes including 
age and health utilities and QALYs (refer to Section 4.3.1) are periodically updated. 
Next, non-disease-specific all-cause mortality is determined in the accounting module 
and recidivism after successful treatment. Outcomes are measured to draw insights into 
the long-term health and economic effects of smoking cessation. 
We used life tables from the Centers for Disease Control and Prevention 
(CDC)/National Center for Health Statistics (NCHS) on age-specific, gender-specific, all-
cause mortality in the American population [Rogers and Powell-Griner, 1991 (in 
Reifsnider, 2011)] to determine non-disease-specific death. The CDC/NCHS data on all-
cause mortality in the American population includes deaths from diseases we are 
interested in tracking in the model (i.e. lung cancer, COPD, stroke, CHD) but will include 
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―healthy‖ nonsmokers as a potential balance. We expect the incidence of death due to 
lung cancer, COPD, stroke, and heart disease to be lower in the healthy, nonsmoking 
population, which may help counter some of the possible/theoretical double counting of 
deaths in the model. It is unclear how to fully separate these risks at this time since we do 
not have a measure for ―all-cause mortality, excluding deaths from lung cancer, COPD, 
stroke, and heart disease‖. 
Using the published literature, we estimated the probability of recidivism after 
successful treatment (Table 4.8). Former, successfully treated, smokers can be assumed 
to relapse according to annual probability, which is based upon the total time abstinent; 
that is to say, the longer a former smoker has remained abstinent from smoking, the more 
likely he/she is to continue to refrain. There is no time period after which a former 
smoker has no risk of relapse. Gilpin, Pierce, and Farkas (1997; in Reifsnider, 2011) 
established in their cohort study of 1449 former smokers that even after 10 years of 
abstinence from smoking, there was no time period after which former smokers had no 
risk of relapse. Therefore, although the risk of relapse diminishes significantly over time, 
no former smoker is ever completely immune to the potential for relapse. Recidivism 
rates depend on the number of years abstinent and are not treatment specific. 
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Table 4.8: Probability of recidivism after 12 months continuous abstinence (defined as non-treatment-
specific, prolonged abstinence beyond 12 months). 
Time period  
Proportion relapsed 
(among those who 
were continuously 
abstinent at 12 mos) 
Reference* 
Years 1-2 0.165 (0.09-0.24) 
Hughes et al, 2008; Gilpin, Pierce and Farkas, 1997; Wetter et al, 
2004 
Years 2-5 0.097 (0.024-0.17) Wetter et al, 2004; Hughes et al, 2008; Krall et al, 2002 
Years 5-10 0.0425 (0.005-0.08) Wetter et al, 2004; Krall et al, 2002; Hughes et al, 2008 
Years 10+ 0.0055 (0.001-0.01) Cromwell et al, 1997; Krall et al, 2002 
* Refer to Reifsnider (2011) 
 
In addition to updating patient characteristics, the model generates statistics on 
smoking prevalence, incidence of relapse, average QALYs gained due to an intervention 
(i.e. effectiveness), death from smoking-related conditions, smoking cessation treatment 
costs, and costs associated with managing a smoking-related chronic disease or 
exacerbation (refer to Section 4.3.2 for cost information). Epidemiologic and economic 
outcomes can be viewed annually or cumulatively.  
4.3 Health and economic measures 
4.3.1 Quality of life 
Quality-adjusted life year (QALY) is a measure of disease burden on both quality 
and quantity of life and can account for morbidity and mortality on quality of life. A 
QALY can be thought of as a year of life quantified by the quality of life or value of 
living in a particular state of health. The quality of life element is measured in terms of 
health utilities. The basic concept behind a QALY is that the amount of time spent in a 
particular health state is weighted by a health state utility score which attempts to reduce 
multi-dimensional health outcomes to a single representation or measure of health. Health 
state utility scores represent the severity of a disease relative to perfect health and are 
scaled between 0 (indicating death) and 1 (indicating perfect health). QALYs provide a 
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common measurement to compare treatment options in terms of health related quality of 
life by quantifying how much someone‘s life could be extended or improved by an 
intervention.  
Health state utilities, as a measure of quality of life associated with particular 
conditions, were drawn from the peer-reviewed literature (Table 4.9). We incorporated 
gender- and age-specific utility values, where possible. We assumed that smokers in good 
health had a slightly lower utility than former smokers in good health and that quality of 
life decreased with age, in accordance with the literature (Table 4.10). 
Table 4.9: Health state utility values for smoking-related co-morbidity. 
Co-morbidity Utility Reference* 
CHD 
0.645  
(0.50-0.79) 
Gold et al, 1998; Sullivan and 
Ghushchyan, 2006; Barton et al, 2008 
Stroke   
      Months 0-2 after first stroke event 
0.425  
(0.33-0.52) 
Wolf et al, 1992; Hoerger et al, 2004; 
Sturm et al, 2002; Tengs and Lin, 2003 
     Months 2+ after first stroke event  
     (improvement after rehabilitation) 
0.725  
(0.55-0.90) 
Tengs et al, 2001, 2003; Duncan et al, 
2000; Howard et al, 2008; Barton et al, 
2008; Mittmann et al, 1999; Tengs and 
Lin, 2003 
      After subsequent/second stroke  
      (lasting disability) 
0.24  
(0.15-0.33) 
Howard et al, 2008; Tengs and Lin, 
2003 
Lung Cancer 
0.50  
(0.39-0.61) 
Gold et al, 1998; Trippoli et al, 2001 
COPD   
      Baseline mild disease 
0.82  
(0.81-0.83) 
Spencer et al, 2005; Rutten-van Molken 
et al, 2006 
      Baseline moderate disease 
0.775  
(0.72-0.83) 
Spencer et al, 2005; Rutten-van Molken 
et al, 2006 
      Baseline severe disease 
0.70  
(0.67-0.73) 
Spencer et al, 2005; Rutten-van Molken 
et al, 2006 
      Minor exacerbation (3 mos) mild disease 0.72 Spencer et al, 2005 
      Minor exacerbation (3 mos) moderate 
disease 
0.658 Spencer et al, 2005 
      Minor exacerbation (3 mos) severe disease 0.475 Spencer et al, 2005  
      Major exacerbation (3 mos) mild disease 0.52 Spencer et al, 2005 
      Major exacerbation (3 mos) moderate 
disease 
0.45 Spencer et al, 2005 
      Major exacerbation (3 mos) severe disease 0.41 Spencer et al, 2005 
CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease 
* Refer to Reifsnider (2011) 
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Table 4.10: Health state utility values for current and former smokers.  
Current smokers Female utility value Male utility value 
Age 24 and younger* 0.91 0.93 
Age 25 - 29 0.89 0.91 
Age 30 - 34 0.87 0.88 
Age 35 - 39 0.84 0.86 
Age 40 - 44 0.82 0.83 
Age 45 - 49 0.80 0.81 
Age 50 - 54 0.78 0.78 
Age 55 - 59 0.76 0.76 
Age 60 - 64 0.74 0.74 
Age 65 - 69 0.72 0.71 
Age 70 and older* 0.70 0.69 
Former smokers Female utility value Male utility value 
Age 24 and younger* 0.94 0.95 
Age 25 - 29 0.92 0.93 
Age 30 - 34 0.9 0.93 
Age 35 - 39 0.89 0.92 
Age 40 - 44 0.87 0.9 
Age 45 - 49 0.86 0.89 
Age 50 - 54 0.84 0.87 
Age 55 - 59 0.82 0.85 
Age 60 - 64 0.79 0.83 
Age 65 - 69 0.77 0.8 
Age 70 and older* 0.75 0.78 
* Assumption; Note: quality of life expressed as mean, where 1.0 is equal to 
optimum health and 0.0 is equal to death 
Refer to Reifsnider (2011) 
 
Incorporating concepts from financial analyses and the health state utilities leads 
to the development of the QALY equation. A common practice in economic evaluations 
is to discount both future costs and benefits. Discounting in the context of economic 
evaluations deals with time preference and implies that costs and benefits occurring at 
different points in time are valued differently. That is, individuals prefer to enjoy benefits 
in the present while postponing any negative effects. For example, taking into account the 
opportunity cost of investing now rather than in the future would mean that future costs 
must be discounted. Discounts are applied on an annual basis. Expenses sustained during 
the first year would not be discounted. Let us assume that a standard annual discount rate 
of 3.0 percent is applied for all economic outcomes. Expenses sustained during the 
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second year would then be discounted by 3.0 percent which means that these expenses 
would be divided by 1.03. Expenses acquired during the third year would be divided by 
1.03
2
 and each consecutive year would be discounted by an additional 3.0 percent. 
Therefore the discount factor is given by equation (2) where r is the annual discount rate 
and t is time in years. 
                                                  Discount factor =  (4.1) 
 
Similarly, this economic concept of discounting is utilized in health care management. 
Annual discount rates are applied to health outcomes to account for the fact that health is 
worth more now than later. 
Equation (1) was used to calculate the aggregate quality of life-years over the 
patient‘s lifetime and is the sum of all QALYs associated with different health states over 
the natural lifetime of the patient (i.e. for each year of life in each health state, the 
relative/weighted value (utility) of that year in that health state). We define t as the time 
in years in which the patient is cycling through the simulation model.  The health state 
utility during year t is defined by Ut and represents an annual assessment of quality of 
life. Ut can be thought of as the ―expense‖ to the patient of living in a certain health state 
during year t. We define T as the total number of years the patient cycles through the 
simulation model until death, and r is the annual discount rate applied for all economic 
and health outcomes. A standard annual discount rate of 3.0 percent was applied for all 
economic and health outcomes [Gold et al., 1996]. For example, person A is healthy in 
year 1 (utility value = 1), has a stroke in year 2 (utility value = 0.5), goes through 
rehabilitation and attains some functional recover in year 3 (utility value = 0.75), and dies 
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at the beginning of year 4 (utility value = 0). This person‘s QALY over the 4 year period 
of time is 1 + 0.485437 + 0.706947 + 0 = 2.19238. 
  (4.2) 
 
4.3.2 Costs 
 We use 2010 costs of co-morbidities and smoking cessation products. Treatment 
is paid for upfront; if a patient dies during year one then the total cost of treatment has 
been incurred. Costs of pharmacological interventions are summarized in Table 4.11. 
Zero cost is associated with the non-pharmacologic-assisted option. Cost for each co-
morbidity and event costs (2010 values, $US) were derived from multiple sources and are 
shown in Table 4.12.   
Table 4.11: Costs (2010 values, $US) of pharmacological treatment. 
Treatment 
Annual cost in 
2010 US$ 
Reference 
NRT $485.29 Howard et al, 2008 
Bupropion $348.69 Red Book: Pharmacy‘s 
Fundamental Reference 2010 
Varenicline $430.53 Red Book: Pharmacy‘s 
Fundamental Reference 2010 
Non-pharmacologic-assisted $0.00  
NRT = Nicotine Replacement Therapy 
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Table 4.12: Cost (2010 values, $US) of treating co-morbidity and event costs. 
Co-morbidity/Event 
Annual cost in 
2010 $US 
Reference* 
Cost of treating CHD   
      First year after diagnosis $8,930 Tsevat et al, 2001; 
Howard et al, 2008 
      Subsequent years after diagnosis $4,239 Tsevat et al, 2001; 
Howard et al, 2008 
Cost of treating stroke   
      First year after diagnosis $41,391 Taylor et al, 1996 
      Subsequent years after diagnosis $17,688 Taylor et al, 1996 
Phase-specific cost of treating lung cancer   
      Initial treatment phase (5.7 mos) $13,759 Kuticova et al, 2005 
      Secondary treatment phase (7.4 mos) $4,468 Kuticova et al, 2005 
      Terminal treatment phase (5.6 mos) $11,249 Kuticova et al, 2005 
      % receiving terminal treatment only (no initial 
treatment) 
9% 
Kuticova et al, 2005 
      % receiving secondary treatment after failing initial    
treatment 
29% 
Kuticova et al, 2005 
      % receiving terminal treatment immediately after failing 
initial treatment  
27% 
Kuticova et al, 2005 
Annual cost of treating COPD $5,369 Halpern et al, 2003 
CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease 
* Refer to Reifsnider (2011) 
 
We seek to assess the gains in health relative to the costs of different health 
interventions, therefore annual discounting was also applied to total costs (i.e. treatment 
cost, costs of co-morbidity, co-morbidity event costs). Discounting of costs assumes that 
a dollar in the present is worth more than a dollar in the future. Let  represent the total 
cost incurred during year t. Equation (2) was used to calculate the sum of all costs over 
the lifetime of the patient. 
  (4.3) 
 
4.4 Model Accreditation 
Integrated practices were employed during the model development process to 
ensure the credibility of the model. First, the assumptions underlying the conceptual 
model were established based upon consultations that took place with clinicians during 
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the formative stages of the simulation model. Additionally, discussions with clinicians 
established that the model structure and causal relationships reasonably represent the 
actual system. During the implementation stages of the model, testing verified that the 
logic and mathematical correlations behind the simulation model operate according to 
model specifications. In addition to the interactions of the aggregate model, each sub-
module was evaluated to determine the appropriate level of detail. Next, input data and 
performance of output measures were assessed during the modeling building process to 
substantiate model accuracy in accordance with the models intended purpose. Clinicians 
performed both qualitative and quantitative analysis of output behaviors to confirm that 
the predicted values were of reasonable magnitude. 
4.5 Conclusions 
We developed a discrete event simulation model to explore comparative 
effectiveness of various smoking cessation options available to smokers in a US 
population. Recognizing that smoking has significant health impacts in terms of 
morbidity and mortality from smoking-related diseases, this model expands upon the 
current literature by (1) simultaneously comparing multiple pharmacologic and non-
pharmacologic options for smoking cessation, which many clinical trials have failed to 
do, and (2) using an innovative modeling approach, discrete event simulation, which 
allows for individual-level variation in smoking intensity, risk, treatment adherence, and 
relapse to be taken into account in assessing the effectiveness of various smoking 
cessation strategies. 
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In terms of limitations and ongoing research needs, we identified a need for better 
smoking-related disease risk data by pack-years. Much of the available data on health 
risks from smoking is reported according to general categories of ―never smoked‖, 
―former smoker‖, ―light current smoker‖ and ―heavy current smoker‖, the latter two of 
which are not well defined and not well validated. Additionally, recognizing that smoking 
status and disease risk are both heavily dependent on socioeconomic and socio-
demographic characteristics, it would be useful in future models to incorporate additional 
information about race/ethnicity, education, income/wealth, and occupation, provided 
good data are available. These individual-level factors have been shown in the literature 
to be important confounders or mediators affecting the causal relationship between 
smoking and disease incidence.  Another limitation of this work is that we did not 
consider geographic or environmental factors related to smoking and disease risk; future 
work could compare risk of recidivism based on location (e.g., different states, urban 
versus rural) or environment (e.g., occupational environment, including other 
environmental exposures such as asbestos or atmospheric pollution). 
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CHAPTER FIVE 
 
ESTIMATING COST-EFFECTIVENESS OF ALTERNATVE SMOKING 
CESSATION STRATEGIES 
 
 
 The purpose of this chapter is to evaluate and analyze the results of the simulation 
model presented in Chapter 4. We introduce our key statistic for assessing cost-
effectiveness. A detailed comparative and sensitivity analysis of smoking cessation 
alternatives is presented and we discuss potential health policy impacts associated with 
the predictions of the model. 
5.1 Incremental cost-effectiveness ratio 
In this section we introduce analytical methods for comparing alternative 
treatment strategies. The incremental cost-effectiveness ratio (ICER) is a standard 
measure used to compare the cost-effectiveness of two treatment options. ICERs provide 
a common unit of measurement to estimate the additional cost and health outcome 
(measured in QALYs, refer to Chapter 5.3.1) obtained through an intervention. The ICER 
is computed by dividing the incremental cost (difference in average cost associated with 
two interventions) by the incremental health benefits (difference in average QALY of two 
interventions). Comparing different treatments in this manner answers questions about 
whether an intervention is efficient and comparatively efficient. Mathematically, the 
ICER is represented as follows: 
 
(5.1) 
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We let  and  signify the expected cost of the investigated treatment (  and the 
expected cost of the control treatment ( , respectively. Similarly, the expected health 
effectiveness of  and the expected health effectiveness of are denoted by  and 
, respectively.  
 In this dissertation, the parameters for the ICER are estimated from the simulation 
model (presented in Chapter 4) and therefore the true population cost and effectiveness is 
unknown with certainty. We can easily obtain confidence intervals (CIs) around the 
sample costs and effects, however in cost-effectiveness analysis we care about the 
uncertainty surrounding the ICER. This is not straightforward because when  and  
are two normal random variables (each variable is associated with a mean and variance) 
then the ratio has a standard Cauchy distribution. A Cauchy distributed variable does not 
have a theoretical mean and variance however it is characterized by its mode and median 
values. Therefore methods have been introduced to calculate CIs of Cauchy distributed 
ICERs including nonparametric bootstrapping [Hunink et al, 1993; Briggs, 1997; 
Campbell and Torgerson, 1999], Fieller‘s method [Chaudhary and Stearns, 1996], and the 
delta method [O‘Brien et al., 1994]. We focus on the use of nonparametric bootstrapping 
for significance testing of the ICER. 
 Black (1990) first introduced the incremental cost-effectiveness plane (Figure 5.1) 
to explain the comparative cost-effectiveness of bootstrap ICER estimates. The horizontal 
axis measures the incremental effectiveness of  and the incremental cost of  is 
measured by the vertical axis. Each of the four quadrants implies a different level of cost-
effectiveness. Points that imply an intervention is more effective while saving money 
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(dominant) fall in the south east (SE) quadrant. The north east (NE) quadrant indicates 
cost-effectiveness where health effect is positive at higher cost. If points lay in the north 
west (NW) quadrant, higher cost is associated with lower effectiveness and the 
intervention is excluded. When both cost and effect are low, points sit in the south west 
(SW) quadrant, and it is questionable whether a treatment is cost-effective compared to 
the control treatment.  
Δ Cost [(C), $US]  
 
NW 
 
Excluded 
(ΔE<0, ΔC>0) 
 
NE 
 
Cost-Effective 
(ΔE>0, ΔC>0) 
 
 
 
 
 
 
 
 
 
Δ Effect [(E), QALY] 
 
 
 
Questionable 
(ΔE<0, ΔC<0) 
 
SW 
 
 
 
 
Dominant 
(ΔE>0, ΔC<0) 
 
SE 
 
 
Figure 5.1: Incremental cost-effectiveness plane (NE = northeast quadrant; NW = northwest quadrant; SE = 
southeast quadrant; SW = southwest quadrant; QALY = quality adjusted life year). 
 
The cost-effectiveness plane helps answer questions about sampling uncertainty 
(e.g. what is the probability  is cost-effective relative to ). Estimates of treatment 
cost-effectiveness are important to health decision-makers who make determinations such 
as whether or not a treatment should be reimbursed. General rules for deciding which 
treatment (  or ) to choose are given in Table 5.1 [Cohen and Reynolds, 2008]. 
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Table 5.1: Implications of the cost-effectiveness plane. 
Quadrant Implication 
NE (+)  (investigated treatment) is cost-effective – cost-increasing tradeoff 
SE (-)  (investigated treatment) is dominant – choose  
SW (-)  (investigated treatment) is questionable – cost-reducing tradeoff 
NW (+)  (control treatment) is dominant – choose  
 
We acknowledge that there are limitations with using the ICER statistic. When 
significant uncertainty exists about the sign of the ICER it is difficult to interpret CIs 
around the ICER. ICERs located in the NE and SW quadrants (both yielding positive 
values) are hard to distinguish, as are ICERs falling in the NW and SE quadrants (both 
having negative values). Different quadrants indicate very different conclusions about the 
cost-effectiveness of the investigated treatment ( ). For example, ICERs located in the 
SE quadrant indicate that  is dominated by  and ICERS sitting in the NW quadrant 
indicate opposite results, that  is dominant. Therefore, reasonable caution should be 
taken when interpreting cost-effectiveness studies. 
5.2 Base-case analyses 
 This section presents the base case results of the simulation model to estimate 
health and economic outcomes of alternative smoking cessation strategies. Results of a 
cost-effectiveness analysis on base-case estimates are provided. 
5.2.1 Simulation parameters 
A cohort of 10,000 individuals was followed annually over a horizon of 1 year, 10 
years, 30 years, and lifetime with output measures observed over five scenarios, one 
simulation run for each intervention of interest and one simulation run with no treatment 
attempt. Cost of treatment options and smoking-related disease and health utility values 
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are summarized in Chapter 4.3. All costs and QALYs were discounted at an annual rate 
of 3%. 
To obtain tighter 95% confidence intervals around our performance values, 75 
replications were carried out leading to sufficiently small half-widths for most output 
variables. Common random numbers (CRNs) were applied to reduce stochastic variation 
between runs. CRNs are particularly important in disease modeling when comparing 
different treatment arms [Stout and Goldie, 2008].  
5.2.2 Base-case results 
The reader should refer to Table 5.2 for results of smoking prevalence over time. 
Among smokers attempting to quit smoking, 2 year recidivism rates among those alive at 
follow-up were the following: nicotine replacement treatment, 89.13%; bupropion, 
81.14%; varenicline, 81.98%, and non-pharmacologic-assisted, 95.84%. Nicotine 
replacement treatment, bupropion, varenicline, and non-pharmacologic-assisted had a 
recidivism rate of 93.67%, 89.07%, 89.55%, 97.58% among those alive at 30 years, 
respectively. 
Table 5.2: Smoking prevalence among those alive at follow-up. 
 2 years 10 years 30 years Lifetime 
NRT 89.13 93.42 93.67 N/A 
Bupropion 81.14 88.60 89.07 N/A 
Varenicline 81.98 89.10 89.55 N/A 
Non-pharmacologic-assisted 95.84 97.49 97.58 N/A 
No Treatment 100.00 100.00 100.00 N/A 
NRT = Nicotine Replacement Therapy; N/A = not applicable  
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Table 5.3: Prevalence of smoking-related disease. 
 2 years 10 years 30 years Lifetime 
NRT     
      CHD 1.04 5.95 20.07 31.78 
      At least one stroke 1.17 5.55 13.38 17.44 
            One stroke 1.17 5.45 12.72 16.13 
            Multiple strokes 0.00 0.10 0.66 1.32 
      Lung Cancer 0.04 0.23 0.96 1.73 
      COPD 0.81 3.81 9.18 12.07 
      At least one co-morbidity 3.03 15.03 39.81 54.65 
Bupropion     
      CHD 1.00 5.78 19.71 31.31 
      At least one stroke 1.16 5.58 13.34 17.43 
            One stroke 1.16 5.48 12.69 16.13 
            Multiple strokes 0.00 0.09 0.65 1.31 
      Lung Cancer 0.03 0.22 0.92 1.69 
      COPD 0.79 3.66 8.92 11.72 
      At least one co-morbidity 2.96 14.74 39.22 53.96 
Varenicline     
      CHD 1.02 5.83 19.76 31.32 
      At least one stroke 1.17 5.59 13.41 17.50 
            One stroke 1.17 5.49 12.74 16.19 
            Multiple strokes 0.00 0.10 0.67 1.31 
      Lung Cancer 0.03 0.23 0.92 1.68 
      COPD 0.78 3.67 8.94 11.79 
      At least one co-morbidity 2.98 14.83 39.35 54.10 
Non-pharmacologic-assisted     
      CHD 1.05 6.03 20.31 32.09 
      At least one stroke 1.19 5.62 13.55 17.64 
            One stroke 1.18 5.53 12.87 16.30 
            Multiple strokes 0.00 0.09 0.68 1.34 
      Lung Cancer 0.04 0.26 1.01 1.83 
      COPD 0.82 3.90 9.37 12.31 
      At least one co-morbidity 3.07 15.28 40.34 55.25 
No Treatment     
      CHD 1.06 6.11 20.48 32.27 
      At least one stroke 1.21 5.66 13.55 17.62 
            One stroke 1.20 5.56 12.87 16.29 
            Multiple strokes 0.00 0.10 0.68 1.33 
      Lung Cancer 0.04 0.27 1.05 1.88 
      COPD 0.83 3.99 9.56 12.48 
      At least one co-morbidity 3.12 15.48 40.67 55.56 
NRT = Nicotine Replacement Therapy; CHD = coronary heart disease; COPD = chronic obstructive 
pulmonary disease 
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Table 5.4: Prevalence of mortality. 
 2 years 10 years 30 years Lifetime 
NRT     
      CHD 0.58 5.09 18.80 30.47 
      Stroke 0.41 1.96 4.93 6.59 
            After one stroke 0.41 1.93 4.69 6.10 
            After multiple strokes 0.00 0.03 0.24 0.49 
      Lung Cancer 0.01 0.14 0.70 1.33 
      COPD 0.01 0.12 0.75 1.46 
      All-causes 0.78 4.96 24.46 60.15 
      Total 1.78 12.28 49.64 100.00 
Bupropion     
      CHD 0.56 4.95 18.46 30.01 
      Stroke 0.41 1.99 4.92 6.60 
            After one stroke 0.40 1.96 4.67 6.11 
            After multiple strokes 0.00 0.03 0.25 0.49 
      Lung Cancer 0.01 0.13 0.67 1.29 
      COPD 0.01 0.12 0.74 1.43 
      All-causes 0.78 4.96 24.61 60.67 
      Total 1.76 12.15 49.41 100.00 
Varenicline     
      CHD 0.57 4.98 18.51 30.05 
      Stroke 0.41 1.98 4.93 6.61 
            After one stroke 0.41 1.94 4.69 6.12 
            After multiple strokes 0.00 0.03 0.25 0.49 
      Lung Cancer 0.01 0.14 0.68 1.29 
      COPD 0.01 0.13 0.74 1.43 
      All-causes 0.78 4.92 24.62 60.62 
      Total 1.77 12.13 49.48 100.00 
Non-pharmacologic-assisted     
      CHD 0.60 5.14 19.03 30.81 
      Stroke 0.42 2.01 4.98 6.66 
            After one stroke 0.42 1.98 4.73 6.15 
            After multiple strokes 0.00 0.04 0.25 0.50 
      Lung Cancer 0.01 0.16 0.74 1.38 
      COPD 0.01 0.13 0.77 1.50 
      All-causes 0.78 4.91 24.28 59.65 
      Total 1.81 12.35 49.80 100.00 
No Treatment     
      CHD 0.59 5.22 19.18 30.95 
      Stroke 0.41 2.01 5.00 6.68 
            After one stroke 0.41 1.98 4.76 6.19 
            After multiple strokes 0.00 0.04 0.24 0.50 
      Lung Cancer 0.01 0.16 0.77 1.44 
      COPD 0.01 0.13 0.78 1.51 
      All-causes 0.78 4.94 24.36 59.41 
      Total 1.80 12.46 50.09 100.00 
NRT = Nicotine Replacement Therapy; CHD = coronary heart disease; COPD = chronic obstructive 
pulmonary disease 
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Results of the base-case analysis found that on average bupropion was most 
effective at reducing prevalence of lung cancer, COPD, stroke, and CHD. Without 
intervention on average 55.56% of smokers will develop at least one smoking-related 
condition over the lifetime of the simulation. Bupropion was also found on average to 
reduce mortality prevalence the most. Compared with the non-pharmacologic-assisted 
cessation option, all pharmacologic treatments (varenicline, NRT, and bupropion) prevent 
smoking-related disease and death. 
Base-case estimates of average cost and effect are summarized in Figure 5.2. The 
average discounted QALYs a cohort of 10,000 former smokers could accumulate over a 
lifetime is 15.14 (95% CI half-width of 0.01). Average QALYs attained over a lifetime 
when smokers make no attempt at quitting is 14.48 (95% CI, 14.47-14.49) at an average 
cost of $28626 (95% CI, $28464-$28788). The high cost associated with the no treatment 
option is attributable to costs incurred from smoking-related disease.  
  No statistically significant differences were found in the average lifetime costs or 
effects (QALYs) of bupropion (average cost between $28004-$28391, average effect 
between 14.70-14.72) and varenicline (average cost between $28240-$28573, average 
effect between 14.69-14.71). Bupropion was more effective and less costly than NRT. No 
statistical differences were found in cost of bupropion and non-pharmacologic-assisted 
cessation, however effectiveness increases with bupropion by 0.16 QALYs. Average cost 
of varenicline was not statistically different from the other four treatment arms, however 
it was statistically more effective than NRT, non-pharmacologic-assisted, and no 
treatment. The population could increase their average effect over a lifetime by 0.14 
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QALYs with NRT and 0.07 QALYs with non-pharmacologic-assisted cessation with no 
statistical difference in average cost. All options to assist smoking cessation improved 
health outcomes compared with no treatment, however only bupropion did so at lower 
average cost. 
 
Figure 5.2: Average discounted cost and effect of the five treatment arms (with 95% CIs). 
  
  Cost-effectiveness analyses were performed after 2 years, 10 years, 30 years, and 
lifetime and were measured using the ICER statistic (refer to Section 5.1). We first 
calculate ICERs by comparing each treatment option (NRT, bupropion, and varenicline, 
non-pharmacologic-assisted) to no intervention. ICERs The results of the analysis are 
presented in Table 5.5. 
 Regarding NRT, bupropion, and varenicline in reference to no treatment we 
observe that cost-effectiveness improves over time. Costs in year 2, primarily attributable 
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to treatment expense, are high and the health benefits are small. However, over a lifetime 
smoking-related disease and mortality are less, and in turn costs are reduced because cost 
of prevented disease is not accumulated and QALYs are higher. The ICER for bupropion 
versus no treatment is the smallest (-$1857.71) followed by varenicline (-$1005.64). 
Although the incremental cost of NRT is very low compared to bupropion and 
varenicline, it is also less effective by 0.09 and 0.10 QALYs, respectively. 
We have to take caution in assessing the non-pharmacologic-assisted option 
compared to no treatment. This is a case where the negative ICER value is misleading. 
Consider year 10 for example in which the incremental cost is negative (-$102.11), 
however the incremental health effect is zero. Money is saved because incidences of 
smoking-related conditions are reduced however, QALYs are not substantially impacted.  
Table 5.5: Smoking cessation strategies compared to no treatment. 
Treatment 2 years 10 years 30 years lifetime 
NRT 
          Incremental cost $459.98 $316.34 $40.15 -$16.82 
      Incremental effect 0.01 0.04 0.10 0.13 
      ICER $76,663.33 $7,869.15 $389.05 -$124.68 
Bupropion         
      Incremental cost $316.56 $114.36 -$317.76 -$428.76 
      Incremental effect 0.01 0.07 0.18 0.23 
      ICER $30,733.98 $1,636.05 -$1,773.21 -$1,857.71 
Varenicline         
      Incremental cost $399.77 $247.51 -$105.78 -$219.33 
      Incremental effect 0.01 0.07 0.17 0.22 
      ICER $40,792.86 $3,688.67 -$621.50 -$1,005.64 
Non-pharmacologic-assisted         
      Incremental cost -$15.52 -$102.11 -$198.29 -$180.78 
      Incremental effect 0.00 0.02 0.05 0.07 
      ICER N/A -$6,462.66 -$4,157.02 -$2,760.00 
 
We next analyzed ICERs over a lifetime horizon by comparing the four smoking 
cessation strategies to each other (NRT, bupropion, varenicline, non-pharmacologic-
assisted) in a successive stepwise manner based on costs incurred and effects (measured 
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in QALYs) achieved. The four competing smoking cessation interventions were ranked 
in order of increasing effectiveness and we compared cost-effectiveness of each strategy 
to the strategy with the next highest QALY [Hallinen et al., 2010]. We want to determine 
how available interventions compare to one another by obtaining maximum effect before 
taking account of cost. Tables 5.6-5.8 show the results of the incremental analysis.  
 In Table 5.6 the negative ICER for varenicline means that by adopting varenicline 
instead of NRT effect is increased and cost is reduced. NRT is dominated by varenicline 
because it is more expensive and less effective and is therefore excluded. The ICERs are 
recalculated (Table 5.7) for the three remaining treatment options. We observe from 
Table 5.7 that non-pharmacologic-assisted is dominated by varenicline and is the next 
alternative excluded. Table 5.8 compares bupropion versus varenicline to show that 
bupropion is the dominant option.  
Table 5.6: Stepwise comparison of smoking cessation interventions – step one. 
Treatment 
Mean Cost 
(C) 
Mean 
Effect* (E) 
Incremental 
Cost (ΔC) 
Incremental 
Effect (ΔE) 
ICER 
(ΔC/ΔE) 
Non-pharmacologic-assisted $28,445.29 14.55 $28,445.29 14.55 $1955.37 
NRT $28,609.25 14.62 $163.95 0.07 $2359.63 
Varenicline $28,406.74 14.70 -$202.50 0.08 -$2436.19 
Bupropion $28,197.31 14.71 -$209.44 0.01 -$16452.10 
* Effect is measured in QALYs 
 
Table 5.7: Stepwise comparison of smoking cessation interventions – step two. 
Treatment 
Mean Cost 
(C) 
Mean 
Effect* (E) 
Incremental 
Cost (ΔC) 
Incremental 
Effect (ΔE) 
ICER 
(ΔC/ΔE) 
Non-pharmacologic-assisted $28,445.29 14.55 $28,445.29 14.55 $1955.37 
Varenicline $28,406.74 14.70 -$38.55 0.15 -$252.62 
Bupropion $28,197.31 14.71 -$209.44 0.01 -$16452.10 
* Effect is measured in QALYs 
 
Table 5.8: Stepwise comparison of smoking cessation interventions – step three. 
Treatment 
Mean Cost 
(C) 
Mean 
Effect* (E) 
Incremental 
Cost (ΔC) 
Incremental 
Effect (ΔE) 
ICER 
(ΔC/ΔE) 
Varenicline $28,406.74 14.70 $28,406.74 14.70 $1932.45 
Bupropion $28,197.31 14.71 -$209.44 0.01 -$16452.10 
* Effect is measured in QALYs 
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5.3 Uncertainty Analyses 
 To allow for uncertainty in the economic evaluation, we first perform a 
probabilistic sensitivity analysis on certain base-case estimates. Next, key parameters are 
varied in univariate and multivariate sensitivity analyses to estimate the influence of 
different parameters on the results. Various factors influence the choices of health policy 
decision-makers, therefore we assess the sensitivity, acceptability, and efficiency of the 
results obtained from the simulation.  
 5.3.1 Stochastic uncertainty in comparing costs and effects 
 Probabilistic sensitivity analysis was performed to confirm the validity of the 
base-case incremental cost-effectiveness ratios (ICERs) for bupropion compared to 
varenicline. In Section 5.2.2 we explained the uncertainty for the average cost and effect 
and observed no statistical difference between bupropion and varenicline. Comparison of 
bupropion to varenicline (Table 5.8) showed varenicline is dominated by bupropion. In 
this section we assess the uncertainty for the incremental cost and effect ratio of 
bupropion in reference to varenicline.  
We applied the nonparametric bootstrap method using the cost and effect 
estimates of the two treatment strategies obtained from the simulation to estimate a 
confidence interval (95%) for the ICER. Four steps were required to produce a bootstrap 
distribution for the ICER. First, paired cost and effect estimates from the simulation for 
bupropion were sampled with replacement. The sample size was that of the original 
sample [the number of replications in the DES model (i.e. 75)]. We obtain a new estimate 
for average cost and effect with bupropion. Second, cost and effect pairs for the control 
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treatment (i.e. varenicline) were sampled with replacement 75 times and a new estimate 
for average cost and effect with the control treatment was attained.  Next, the ICER of the 
bootstrapped re-samples was computed. Sampling and calculation of the ICER was 
performed 1000 times [Briggs et al., 1997; Campbell and Torgerson, 1999]. Construction 
of the 95% confidence interval (CI) for the bootstrapped ICERs was achieved using the 
percentile method [Briggs et al., 1997; Campbell and Torgerson, 1999]. ICER estimates 
were ranked from smallest to largest and the lower and upper bounds of the CI were 
represented by the 25
th
 and 976
th
 observations, respectively.  The results of bootstrapping 
to compare bupropion to varenicline are provided in Table 5.9. 
Table 5.9: Incremental costs and effects (QALY) of 1,000 bootstrapped comparisons of Bupropion vs NRT. 
Bupropion versus varenicline Mean (CI) 
Median ICER 
[(ΔC/ ΔE), bootstrap CI] 
 
    Incremental Cost (ΔC) -208.86 -13738.83 
(-208723.42, 14518.98) 
 
    Incremental Effect (ΔE) 0.01  
 
 The 1000 ICER estimates were plotted on the cost-effectiveness plane (Figure 
5.3) allowing us to evaluate uncertainty of our bootstrapped ICERs. In the base-case 
analysis bupropion was found to dominate varenicline (indicated by the square in Figure 
5.3). Although the estimates cover all four quadrants, indicating some uncertainty about 
whether bupropion is dominant or cost-effective, the scatter plot shows bupropion to be 
the dominant (more effective and less costly) treatment strategy with a high probability of 
0.849. This supports the results of our base-case analysis. All four quadrant probabilities 
are summarized in Table 5.10.  
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Figure 5.3: Scatter plot of the 1,000 bootstrap pairs presented on the cost-effectiveness plane of bupropion 
vs. varenicline. 
 
Table 5.10: Quadrant probabilities of bupropion vs. varenicline. 
Quadrant Probability 
NE (bupropion is cost-effective) 0.055 
NW (varenicline dominates) 0.006 
SW (bupropion is questionable) 0.090 
SE (bupropion dominates) 0.849 
    
5.3.2 Sensitivity analysis 
 Multiple one-way sensitivity analyses were performed on the lifetime ICER to 
assess the robustness of the simulation when key input parameters are varied. These 
parameters include all health state utility values of the smoking-related diseases, discount 
rate on costs and QALYs, abstinence rates, and treatment costs. Holding other variables 
constant, we varied the group of recidivism rates at a low and high value (refer to table 
4.8) in a multi-way sensitivity analysis. Finally, sensitivity analysis is restricted to subsets 
of the base-case population (e.g. assessing a group of all females).  
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First, health state utilities were altered one at a time at the low value and high 
value presented in Table 4.9. The discount rate (on both costs and QALYs) was adjusted 
to 1% and 5% [Weinstein et al., 1996]. Results show that our model is strong in that none 
of the incremental costs and incremental effects resulting from multiple univariate 
sensitivity analyses on health state utilities differed from our base-case estimate. Base-
case ICER for bupropion versus varenicline ( -$16452.10 per QALY saved) was sensitive 
to the discount rate at 1% and 5% with a percent change to the base-case ICER of 29% 
and -30%, respectively.   
Next, we evaluated the efficacy rates (percent who stop smoking after the first 
year) for bupropion and varenicline over the range obtained from our meta-analysis 
(Table 4.2; Bupropion: 15%-30%, Varenicline: 18%-25%) using a step size of 1%. 
Figure 5.5 shows the impact of the abstinence rate on cost per QALY for two treatments, 
bupropion and varenicline. Then, we examined implications of treatment cost of 
bupropion and varenicline when the price of treatment is $0 to $800 with step size $100. 
Figure 5.6 shows the impact of varying the cost of bupropion and varenilcline. We 
observe in Figure 5.5 that if the treatment efficacy of bupropion and varenicline are 
equal, the cost per effect ($/QALY) is less for bupropion. Figure 5.6 shows that if cost 
treatment for bupopion and varenicline are the same, cost per effect ($/QALY) is always 
less for bupropion. Treatment efficacy is higher for bupropion in reference to varenicline, 
therefore the QALY value (denominator) is always higher for bupriopion and the cost per 
effect ratio is smaller. Therefore, bupropion is not only less expensive, but also more 
effective. 
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Figure 5.4: One-way sensitivity analysis of treatment efficacy of bupropion and varenicline. 
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Figure 5.5: One-way sensitivity of treatment cost of bupropion and varenicline. 
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  Multi-way sensitivity analysis of recidivism rates was performed at low and high 
values (Table 4.8). Refer to Table 5.11 for a summary of these results. Results of the 
multi-way sensitivity analysis at low recidivism rates place the ICER in the NE (cost-
effective) quadrant. When recidivism is high, we find that the incremental cost of 
bupropion compared to varenicline is -$317.86 compared to -$209.44 in the base-case. 
Incremental effect is much smaller (0.0007 QALYs) than the base-case estimate (0.01 
QALYs). 
Table 5.11: Multi-way sensitivity analysis of recidivism rates. 
Recidivism rate Incremental Cost (ΔC) Incremental Effect (ΔE) ICER (ΔC/ΔE) 
Low value $31.45 0.0228 $1,379.43 
High value -$317.86 0.0007 -$454,083.14 
 
ICERs of bupropion in reference to varenicline of an all female and all male 
population are evaluated. Very different results are estimated for an all female cohort 
versus an all male cohort (Table 5.12). For an all female population, bupropion is less 
costly (-$68.33) and slightly more effective (0.0203 QALYs) with an ICER of -$3371.  
When the same simulation is run for an all male population, money is saved (-$92.77), 
however health benefits are also lost (-0.0026). The ICER for an all male cohort is 
$35,914 and a cost-reducing tradeoff must be made in choosing bupropion. 
Last, costs and effects of a young cohort of all 18-year olds and individuals all 50 
years of age at baseline (older age group) are estimated. Among both age groups cost is 
saved while health benefits are gained (Table 5.12). Bupropion is dominant in 
comparison to varenicline in both cases with ICERs of -$49,158 and -14,852 for 
individuals 18 years of age and 50 years of age, respectively. 
 
 107 
 
Table 5.12: Sensitivity analysis by subset of the base-case population. 
Parameter Incremental Cost (ΔC) Incremental Effect (ΔE) ICER (ΔC/ΔE) 
Sex    
      Female -$68.33 0.0203 -$3,371.00 
      Male -$92.77 -0.0026 $35,914.44 
Age    
      18 years of age -$169.20 0.0034 -$49,158.22 
      50 years of age -$207.01 0.0139 -$14,852.23 
 
5.4 Discussion 
In this study, we used estimates of cost and QALY from the simulation presented 
in Chapter 4 of smokers attempting pharmacologic smoking cessation treatment (NRT, 
bupropion, and varenicline), non-pharmacologic-assisted cessation, and no treatment. 
Cost effectiveness was estimated using the incremental cost-effectiveness ratio (ICER) 
statistic. We first assessed the cost-effectiveness of the alternative treatment strategies by 
comparing all treatment options to no treatment. Next a stepwise comparison of the 
treatments was performed where decisions must be made between choosing bupropion 
and varenicline. We found burpropion to be the dominant treatment for smoking 
cessation.  
Probabilistic sensitivity analysis confirmed the base-case findings for bupropion 
versus varenicline and nonparametric bootstrapping showed that bupropion was dominant 
with probability 84.9%. Our simulation was robust to changes in health state utility 
values in our one-way sensitivity analysis. For all female versus all male populations 
cost-effectiveness results differed greatly. In fact, the only case where bupropion was 
cost-reducing resulted when the simulation was run for an all male population. This 
implies that limited health care dollars are better off helping females versus males. 
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Our results differ from previous cost-effectiveness studies of smoking cessation 
therapies where varenicline was found to dominant in comparison to bupropion [Howard 
et al., 2008]. One major difference between these studies and our research is that there 
efficacy rates rely on a single clinical efficacy study. We obtain measures through a 
meta-analysis of studies that investigate the efficacy of smoking cessation strategies. The 
midpoint of the range is used as our base-case estimate of treatment efficacy. We perform 
sensitivity analysis over the range of efficacy rates for bupropion and varenicline. In 
future research, we will examine how the results change when the sample-size-weighted-
average for each treatment efficacy rate is applied.  
In conclusion, we have shown that using discrete-event simulation is a powerful 
tool with which we can examine comparative effectiveness of smoking cessation 
strategies in a diverse patient population. We have further demonstrated that the long-
term benefits of smoking cessation at a younger age significantly accrue over a patient‘s 
lifetime. As such, it is critical for policymakers and insurers to encourage and consider 
providing incentives for smoking cessation as early as possible and for clinicians and 
patients to engage in shared decision making about which treatment strategy would be 
best for the patient in terms of long-term abstinence, overall resources invested, and 
cumulative health risks avoided over time.  
 
 
  
 109 
CHAPTER SIX 
 
CONTRIBUTIONS  
 
 
Chapter 2 introduced a discrete-event simulation (DES) model to quantify the 
public health impact of the maternal obese and diabetic intrauterine environment on 
obesity and diabetes prevalence in subsequent generations. The model was verified using 
longitudinal data and we provided examples of the types of predictions our model can 
generate. This dissertation is the first to apply discrete-event simulation to estimate the 
impact of maternal obesity and diabetes on obesity and diabetes prevalence. 
In Chapter 3 we used a mixed-methods approach, incorporating both statistical 
methods and discrete-event simulation, to examine trends in weight-gain over time 
among white and black women of child-bearing age in the US from 1980 to 2008 using 
United States Census projections and National Health and Nutrition Examination Survey 
(NHANES) data. We addressed the question of how to update changes in clinical 
characteristics over time using data obtained through a cross-sectional study design. We 
responded by developing a method to gain insights into the processes of change of 
attributes using bootstrapping principles and mixed-effects regression models. This was 
used to determine the change in BMI due to age in the simulation model allowing us to 
examine trends in average BMI over generations at the population-level. Our results are 
different than what is currently available in the literature in that our simulation 
projections are based on the population prior to the onset of the obesity epidemic. 
 In Chapter 4 we constructed the first DES model to estimate the cost-effectiveness 
of different smoking cessation strategies available to smokers in the US population. 
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While previous models for comparing therapeutic smoking cessation options use efficacy 
of treatment derived from a single study, we contribute to the literature by combining 
results of different studies to model treatment efficacy. We described the data and model 
assumptions and verification. 
 Chapter 5 provided results of the base-case model to evaluate smoking cessation 
treatments. A sensitivity analysis was performed to understand the comparative 
effectiveness and intrinsic value of four alternative smoking cessation strategies that can 
improve clinical and patient decision-making and subsequent health and economic 
outcomes at the population level. We provided examples of different analyses that can be 
done using results of our model. 
This dissertation contributes to the area of industrial engineering in healthcare by 
providing two US population-level DES models to inform health policy decisions. US 
population-level data structures require special handling and assumptions due to the 
availability of medical data and the nature of the study design. The key element is to be 
able to link mathematical models with the available data. Input measures are important 
because the models are only as strong as the data and assumptions upon which they are 
built. Data taken from multiple sources (United States Census, National Health and 
Nutrition Examination Survey (NHANES), Centers for Disease Control and Prevention 
(CDC)/National Center for Health Statistics (NCHS), and the literature) is not obtainable 
in the desired format, and there is not one method for managing the data. Preparing a 
valid representation of the data is crucial. We illustrate various methods for extracting 
information from the data to make population-level predictions. Specifically,  
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In Chapter 2, data from a longitudinal study was utilized to update attributes (i.e. BMI 
level, diabetes status) of individuals in the simulation. Extracting necessary information 
from this data involved different types of methods. 
 Using the mean and variance of the difference in average BMI (kg/m2) at baseline 
and follow-up of the longitudinal study, annual changes to BMI were computed. 
Updates to BMI values per year were approximated by a normal distribution. 
 Baseline estimates of diabetes prevalence taken from the longitudinal study and 
information on increased likelihood of diabetes in obese versus not obese 
individuals were used to derive baseline estimates of diabetes adjusted by obesity 
status. 
 Annual probabilities of developing diabetes over time based on obesity status 
were deduced using (a) baseline prevalence of obesity and (b) diabetes incidence 
rates follow-up from the longitudinal study, and (c) the increased risk of diabetes 
known to obese versus non-obese individuals. This was accomplished by applying 
the cumulative geometric distribution. 
 Validating BMI and diabetes characteristics over a short time period (i.e. 8 years) 
allowed us to make projections of diabetes prevalence accounting for obese 
individuals having a different/higher risk of diabetes than non-obese individuals. 
 Furthermore, incorporating births into our model and keeping record of an 
individual‘s mother‘s BMI and diabetes characteristics, allowed us to make 
projections of diabetes prevalence over time when children of obese and/or 
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diabetic women had an increased risk of diabetes from children not exposed to 
obesity and/or diabetes during pregnancy. 
In Chapter 3, cross-sectional data of the National Health and Nutrition Examination 
Survey (NHANES) provided US population-level information on BMI. 
 We developed a method for extracting information from the cross-sectional data 
set which allowed us to make US population-level estimates of change in 
attributes (i.e. BMI) over time. This technique combined bootstrap statistical 
methods and mixed-effects regression models. We described how we handled 
cases of missing or insufficient data. This method allowed us to characterize the 
change in weight-gain of white and black women of childbearing age in the US 
prior to the onset of the obesity epidemic. 
 A method for validating our baseline (i.e. 1980) unadjusted average BMI 
projections was presented. 
 Unadjusted projections of average BMI over a 28-year time period were made. 
These projections of average BMI between 1980-2008 are fundamentally 
different from what is currently available in the literature in that we make 
projections of the population before the obesity epidemic took place. Previous 
studies formulate projections on trends of diseases based on population data in 
2000, at which time the obesity (and also diabetes) epidemics had already 
initiated. 
 Estimates of baseline BMI and change in BMI over time from the statistical 
analysis provided population-level estimates for the simulation model (presented 
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in Chapter 2). We proposed two methods for validating that individuals in the 
simulation take on age appropriate characteristics (according to baseline cross-
sectional values): (1) validation of the Census age distribution, and (2) validation 
of average BMI. We demonstrated these methods for projections of white women 
of childbearing age. 
In Chapter 4, information was extracted from data of multiple sources, presenting in 
many different formats. Various statistical methods were applied to represent the data. 
 Disease incidence (for lung cancer, stroke, and CHD) required conversions from 
rates of disease per annum to annual probabilities. For example, given the case rate 
of stroke over a time period, we computed the probability of an individual having a 
stroke in any given year. The cumulative exponential distribution function was 
used in this computation. 
 In other cases (number of COPD exacerbations) where more than one occurrence 
was possible in a year the binomial probability distribution was used to estimate 
annual incidence. 
 Similarly, the number of exacerbations (out of the total annual COPD 
exacerbation) that were major exacerbations was determined using the binomial 
distribution formula.  
In Chapter 5, we apply statistical methods to deduce information from the output 
measures of the simulation (presented in Chapter 4). 
 We introduced the incremental cost-effective ratio (ICER) as a statistic for 
quantifying cost-effectiveness of one treatment relative to another. 
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 Two different methods for comparing costs and health effects (QALYs) of the 
alternative smoking cessation strategies using the ICER were provided. First, we 
made separate comparisons of each treatment option (NRT, bupropion, 
varenicline, and non-pharmacologic-assisted) to the no treatment control group to 
quantify incremental cost per incremental health effect (QALY). Next, the four 
treatment strategies were compared to each other in a successive stepwise manner 
to gain information about how treatments perform in comparison to each other. 
 Like any statistical measure the ICER point estimate is associated with some 
degree of uncertainty. Non-parametric bootstrap procedures allowed us to 
estimate an uncertainty range for the ICER of two treatment options (bupropion 
versus varenicline). We computed the 95% confidence interval for the 
bootstrapped ICERs using the percentile method. Information about the 
uncertainty of cost-effectiveness of a treatment option (bupropion) from the base-
case estimations was provided. 
 Bootstrap estimates were analyzed using the cost-effectiveness plane method 
which allowed us to address questions about the probability of cost-effectiveness 
when comparing two treatment options (bupropion in reference to varenicline). 
While the estimates resulting from the two models are topic-specific, many of the 
modules created for these studies are generic and can easily be transferred to other 
disease models. It is believed that these two models will aid decision makers in 
recognizing the impact that preventative-care initiatives will have, and to evaluate 
possible alternatives. 
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Appendix A 
 
Conditional Probability of Diabetes 
 
 
Diabetes incidence rates taken from the SAHS study are provided in Table A.1. 
 
Table A.1: Incident diabetes rates over the 7.5 year period. 
Age cohort Incidence 
< 30 1.59 
30 – 34 3.41 
35 – 39 5.10 
40 – 44 4.90 
 
Prevalence of obesity in the SAHS population at baseline was 13.7 percent. Obese 
individuals are assumed to be 10.723 times more likely to develop diabetes than 
individuals who were not obese. The calculations are the following: 
P(diabetes) = P(diabetes|obese)P(obese) + P(diabetes|not obese)P(not obese) 
P(diabetes) = P(diabetes|obese)P(obese) + P(diabetes|not obese)(1-P(obese)) 
We know that:  P(diabetes|obese) = (10.723)[P(diabetes|not obese)] 
P(diabetes) = (10.723)(P(diabetes|not obese))P(obese)  
          + P(diabetes|not obese)(1-P(obese)) 
 
For example, the derivation for the probability of diabetes for individuals less than 30 
years of age given obesity status is provided. 
0.0159 = (10.723)(P(diabetes|not obese))(0.137 ) + P(diabetes|not obese)(1-0.137) 
Rearrange the terms: 
0.0159 = P(diabetes|not obese)((10.723)(0.137) + (1-0.137)) 
P(diabetes|not obese) = 0.0068 
P(diabetes|obese) = (10.723)(0.0068) = 0.0729 
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This is the conditional probability of diabetes over 7.5 (round to 8) years. We want the 
annual probability of developing diabetes given obesity status. We use the cumulative 
distribution function (CDF) of a geometric random variable to determine the probability 
of developing diabetes given obesity status in one year.  
The CDF of a geometric random variable X is: 
 
F(x) = P(X ≤ x) = 1 – (1-p)k  k = 1, 2, … 
 
where p is the probability of succeeding on one try. 
If we make independent attempts over and over, the geometric random variable counts 
the number of attempts needed to obtain the first success. The CDF can be interpreted as 
the probability of succeeding within k attempts. 
Referring to the example, the probability of diabetes mellitus given obesity status for individuals 
less than 30 years of age is the following: 
P(diabetes|non-obese) = 1 – (1 – 0.0068)(1/7+1) = 0.0009 
 
P(diabetes|obese) = 1 – (1 – 0.0731)(1/7+1) =  0.0094       
 
Note that a potential drawback of using the geometric distribution is that it satisfies the 
memoryless property.  
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Appendix B 
DES Distribution Input Parameters and Sensitivity Analysis Results 
 
 
Table B.1: Distribution parameters for unadjusted BMI (kg/m
2
) projections and baseline BMI in the 
simulation model. 
  White Women  Black Women 
Age  Mean SD  Mean SD 
15  21.5433 3.4282  22.4345 4.7431 
16  21.7085 3.8278  22.7072 4.8048 
17  21.9470 4.4140  22.9800 5.5909 
18  22.1024 3.6399  23.2527 3.9708 
19  22.2578 3.9704  23.5254 6.4735 
20  22.4132 4.1106  23.7982 4.8807 
21  22.5686 3.7814  24.0709 5.6945 
22  22.7081 4.0617  24.3437 7.6422 
23  22.8623 4.8443  24.6164 4.6313 
24  23.0097 5.4161  24.8891 4.8132 
25  23.1584 4.6566  25.1619 5.8713 
26  23.3071 3.9366  25.4346 5.1306 
27  23.4558 5.1977  25.7074 6.6887 
28  23.6045 5.5674  26.4814 4.9856 
29  23.7392 5.3541  26.6371 7.2702 
30  23.8911 5.3520  26.7927 7.8335 
31  24.0429 5.4873  26.9484 7.2204 
32  24.1591 6.2145  27.1041 6.4911 
33  24.2872 5.6085  27.2598 6.3269 
34  24.4154 4.8513  27.4154 7.1926 
35  24.5435 5.7674  27.5711 6.0806 
36  24.6716 4.7902  27.7268 7.4565 
37  24.7398 5.3306  27.8825 6.9395 
38  24.7448 5.6666  28.0382 6.4886 
39  24.8569 5.5871  28.1938 7.2594 
40  24.9690 5.7611  28.3495 5.2604 
41  25.0811 5.0280  28.5052 7.9332 
42  25.1932 6.0894  28.6609 5.9704 
43  25.3384 5.7728  28.8165 6.5386 
44  25.4582 5.8072  28.9722 5.9604 
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Table B.2: Distribution parameters for BMI (kg/m
2
) updates (annual change in BMI) in the simulation 
model. 
  White Women  Black Women 
Age  Mean SD  Mean SD 
15  0.1652 0.6857  0.2727 0.7316 
16  0.1652 0.6857  0.2727 0.7316 
17  0.1554 0.4935  0.2727 0.7316 
18  0.1554 0.4935  0.2727 0.7316 
19  0.1554 0.4935  0.2727 0.7316 
20  0.1554 0.4935  0.2727 0.7316 
21  0.1554 0.4935  0.2727 0.7316 
22  0.1542 0.3998  0.2727 0.7316 
23  0.1542 0.3998  0.2727 0.7316 
24  0.1487 0.4921  0.2727 0.7316 
25  0.1487 0.4921  0.2727 0.7316 
26  0.1487 0.4921  0.2727 0.7316 
27  0.1487 0.4921  0.2727 0.7316 
28  0.1487 0.4921  0.1557 0.6049 
29  0.1518 0.6816  0.1557 0.6049 
30  0.1518 0.6816  0.1557 0.6049 
31  0.1518 0.6816  0.1557 0.6049 
32  0.1281 0.5886  0.1557 0.6049 
33  0.1281 0.5886  0.1557 0.6049 
34  0.1281 0.5886  0.1557 0.6049 
35  0.1281 0.5886  0.1557 0.6049 
36  0.1281 0.5886  0.1557 0.6049 
37  0.1253 0.5283  0.1557 0.6049 
38  0.1121 0.7154  0.1557 0.6049 
39  0.1121 0.7154  0.1557 0.6049 
40  0.1121 0.7154  0.1557 0.6049 
41  0.1121 0.7154  0.1557 0.6049 
42  0.1121 0.7154  0.1557 0.6049 
43  0.1198 1.0612  0.1557 0.6049 
44  0.1198 1.0612  0.1557 0.6049 
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Table B.3: Sensitivity analysis baseline BMI (kg/m
2
) for age 32 to 37 years. 
  Scenario 1  Scenario 2  Scenario 3 
Age  Mean SD  Mean SD  Mean SD 
32  24.1591 0.3381  24.1235 0.3836  24.1947 0.5568 
33  24.2872 0.3381  24.2279 0.3836  24.3466 0.5568 
34  24.4154 0.3381  24.3323 0.3836  24.4984 0.5568 
35  24.5435 0.3381  24.4368 0.3836  24.6502 0.5568 
36  24.6716 0.3381  24.5412 0.3836  24.8021 0.5568 
37  24.7398 0.2573  24.6327 0.2674  24.9539 0.5568 
  Scenario 4  Scenario 5    
Age  Mean SD  Mean SD    
32  24.1413 0.2556  24.1769 0.3257    
33  24.2576 0.2556  24.3169 0.3257    
34  24.3739 0.2556  24.4569 0.3257    
35  24.4901 0.2556  24.5969 0.3257    
36  24.6064 0.2556  24.7369 0.3257    
37  24.6862 0.1856  24.8468 0.3067    
 
 
Table B.4: Sensitivity analysis updates to BMI (kg/m
2
) for age 32 to 37 years. 
  Scenario 1  Scenario 2  Scenario 3 
Age  Mean SD  Mean SD  Mean SD 
32  0.1281 0.5886  0.1044 0.9597  0.1518 0.6816 
33  0.1281 0.5886  0.1044 0.9597  0.1518 0.6816 
34  0.1281 0.5886  0.1044 0.9597  0.1518 0.6816 
35  0.1281 0.5886  0.1044 0.9597  0.1518 0.6816 
36  0.1281 0.5886  0.1044 0.9597  0.1518 0.6816 
37  0.1253 0.5283  0.1121 0.7154  0.1518 0.6816 
  Scenario 4  Scenario 5    
Age  Mean SD  Mean SD    
32  0.1163 0.5629  0.1400 0.4503    
33  0.1163 0.5629  0.1400 0.4503    
34  0.1163 0.5629  0.1400 0.4503    
35  0.1163 0.5629  0.1400 0.4503    
36  0.1163 0.5629  0.1400 0.4503    
37  0.1187 0.4447  0.1386 0.4312    
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Table B.5: Sensitivity analysis results for average BMI (kg/m
2
) by age cohort and year. 
Year  Age Cohort  Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
1980 
 15 - 19  21.93 21.93 21.93 21.93 21.93 
 20 - 24  22.71 22.71 22.71 22.71 22.71 
 25 - 29  23.44 23.44 23.44 23.44 23.44 
 30 - 34  24.15 24.11 24.18 24.13 24.16 
 35 - 39  24.70 24.63 24.80 24.67 24.75 
 40 - 44  25.21 25.21 25.21 25.21 25.21 
 15 - 44  23.50 23.48 23.52 23.49 23.51 
1990 
 15 - 19  22.42 22.42 22.42 22.42 22.42 
 20 - 24  23.20 23.20 23.20 23.20 23.20 
 25 - 29  23.47 23.47 23.47 23.47 23.47 
 30 - 34  24.21 24.19 24.22 24.20 24.21 
 35 - 39  24.84 24.74 24.96 24.79 24.90 
 40 - 44  25.38 25.23 25.55 25.31 25.47 
 15 - 44  23.97 23.92 24.02 23.94 23.99 
2000 
 15 - 19  22.40 22.40 22.40 22.40 22.40 
 20 - 24  23.17 23.17 23.17 23.17 23.17 
 25 - 29  23.97 23.97 23.97 23.97 23.97 
 30 - 34  24.69 24.68 24.71 24.69 24.70 
 35 - 39  24.83 24.71 24.94 24.77 24.89 
 40 - 44  25.43 25.30 25.58 25.37 25.51 
 15 - 44  24.20 24.15 24.25 24.18 24.23 
2008 
 15 - 19  22.41 22.41 22.41 22.41 22.41 
 20 - 24  23.16 23.16 23.16 23.16 23.16 
 25 - 29  23.93 23.93 23.93 23.93 23.93 
 30 - 34  24.66 24.65 24.68 24.65 24.67 
 35 - 39  25.37 25.27 25.49 25.31 25.42 
 40 - 44  25.72 25.59 25.87 25.65 25.79 
 15 - 44  24.28 24.24 24.33 24.26 24.30 
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Appendix C 
Sample SAS Code 
 
Libname nh1 "M\BMI by Birth Year"; 
data allw; 
  set nh1.nh0123; 
  where race='W'; 
  newid=left(trim(id))||left(trim(seqn)); 
  run; 
 
/*numbers in dataset name correspond to birth years*/ 
/*age is centered to that the intercept is the lowest age 
of the category*/ 
data w5559; 
  set allw; 
  where yob>='1955' and yob<'1959' and age>=15 and age<=23; 
  agec=age-15;  
  run; 
***************************************************** 
*regression example 5559 birth year -- 1955 and 1959* 
***************************************************** 
; 
%let itnum=100; 
%let sampsize=500; 
*SRS means Simple Random Sampling; 
proc surveyselect data=w5559 method=SRS n=&sampsize 
reps=&itnum seed=40070 out=r5559;          
run; 
proc sort data=r5559; by replicate; run; 
*** Full: With Random and method=REML ***  ; 
**NOTE: this includes the main effect of agecat ; 
ods graphics on; 
proc mixed data=r5559 method=REML noclprint=2 empirical; 
  class newid; 
  model bmi=agec/cl solution covb ddfm=res 
outpm=output5559;  
  by replicate ; 
  random intercept/ subject=newid; 
  ods output SolutionF=betaparms;  
run;  
ods select fitstatistics; 
proc reg data=output5559; 
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 model bmi=pred; 
* by replicate; 
run; 
quit; 
ods graphics off; 
proc contents data=betaparms; run; 
*NOTE: First open the output data file betaparms_mix and 
see if the effect columns correspond to what I have used 
below; 
* summary of parameter estimates*********; 
data nh1.betaparms5559 (keep=replicate inter vinter tvinter 
dfinter pvinter b1 vb1 tvb1 dfb1 pvb1); 
retain inter tvinter dfinter b1 vb1 tvb1 dfb1 pvb1; 
set betaparms; 
by replicate; 
if effect eq 'agec' then do;  
 b1 = estimate; vb1=StdErr; tvb1=tvalue; pvb1=Probt; 
dfb1=df; end; 
if effect eq 'Intercept' then do;  
    inter=estimate; vinter=StdErr; tvinter=tvalue; 
pvinter=probt; dfinter=df; end; 
 if last.replicate then do; 
    output; 
  end; 
  else delete; 
run; 
proc means data=nh1.betaparms5559; 
  var b1 inter; 
  run; 
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Appendix D 
Computations for the Smoking Cessation DES Inputs 
 
 
Table D.1: Age distribution of smokers. 
   Male  Female 
Age 
 
Number in 
the US 
Number 
of 
Smokers 
P(age|smoke) 
 
Number in 
the US 
Number 
of 
Smokers 
P(age|smoke) 
18  2,282,042 579,639 0.024  2,162,940 439,077 0.022 
19  2,224,534 565,032 0.023  2,112,751 428,888 0.021 
20  2,188,236 555,812 0.023  2,086,884 423,637 0.021 
21  2,155,654 547,536 0.022  2,062,647 418,717 0.021 
22  2,162,386 549,246 0.022  2,068,296 419,864 0.021 
23  2,154,443 547,229 0.022  2,060,702 418,323 0.021 
24  2,134,690 542,211 0.022  2,039,250 413,968 0.021 
25  2,159,241 548,447 0.022  2,058,541 417,884 0.021 
26  2,157,349 547,967 0.022  2,083,273 422,904 0.021 
27  2,174,226 552,253 0.023  2,125,979 431,574 0.021 
28  2,155,475 547,491 0.022  2,106,378 427,595 0.021 
29  2,070,323 525,862 0.021  2,019,348 409,928 0.020 
30  2,016,724 512,248 0.021  1,968,179 399,540 0.020 
31  1,974,327 501,479 0.020  1,930,843 391,961 0.019 
32  1,945,812 494,236 0.020  1,910,458 387,823 0.019 
33  1,974,872 501,617 0.020  1,939,809 393,781 0.020 
34  1,926,499 489,331 0.020  1,905,546 386,826 0.019 
35  1,962,294 498,423 0.020  1,949,570 395,763 0.020 
36  2,046,138 519,719 0.021  2,037,513 413,615 0.021 
37  2,154,037 547,125 0.022  2,154,393 437,342 0.022 
38  2,205,790 560,271 0.023  2,186,689 443,898 0.022 
39  2,091,135 531,148 0.022  2,088,056 423,875 0.021 
40  2,039,111 517,934 0.021  2,046,859 415,512 0.021 
41  2,037,007 517,400 0.021  2,056,617 417,493 0.021 
42  2,094,378 531,972 0.022  2,114,992 429,343 0.021 
43  2,229,898 566,394 0.023  2,249,584 456,666 0.023 
44  2,251,737 571,941 0.023  2,294,963 465,877 0.023 
45  2,243,116 551,807 0.023  2,294,799 470,434 0.023 
46  2,250,985 553,742 0.023  2,303,860 472,291 0.023 
47  2,263,325 556,778 0.023  2,329,012 477,447 0.024 
48  2,309,119 568,043 0.023  2,359,664 483,731 0.024 
49  2,215,240 544,949 0.022  2,284,705 468,365 0.023 
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50  2,206,404 542,775 0.022  2,280,669 467,537 0.023 
51  2,151,695 529,317 0.022  2,237,945 458,779 0.023 
52  2,088,599 513,795 0.021  2,180,369 446,976 0.022 
53  2,085,043 512,921 0.021  2,169,687 444,786 0.022 
54  1,979,014 486,837 0.020  2,082,836 426,981 0.021 
55  1,912,892 470,571 0.019  2,024,202 414,961 0.021 
56  1,847,781 454,554 0.019  1,959,188 401,634 0.020 
57  1,774,943 436,636 0.018  1,892,368 387,935 0.019 
58  1,769,416 435,276 0.018  1,886,571 386,747 0.019 
59  1,693,399 416,576 0.017  1,820,005 373,101 0.019 
60  1,692,209 416,283 0.017  1,823,349 373,787 0.019 
61  1,665,640 409,747 0.017  1,800,563 369,115 0.018 
62  1,356,184 333,621 0.014  1,481,887 303,787 0.015 
63  1,271,328 312,747 0.013  1,399,272 286,851 0.014 
64  1,254,678 308,651 0.013  1,394,030 285,776 0.014 
65  1,244,631 131,931 0.005  1,396,116 114,482 0.006 
66  1,123,417 119,082 0.005  1,274,736 104,528 0.005 
67  1,021,173 108,244 0.004  1,172,433 96,140 0.005 
68  971,772 103,008 0.004  1,124,069 92,174 0.005 
69  919,903 97,510 0.004  1,073,613 88,036 0.004 
70  877,737 93,040 0.004  1,036,312 84,978 0.004 
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Table D.2: Probability tables for COPD exacerbations 
COPD Level x f(x,p,n) 
Mild
a
 
  
 0 0.5558 
 1 0.3516 
 2 0.0834 
 3 0.0088 
 4 0.0003 
Moderate
b
 
  
 0 0.4606 
 1 0.3940 
 2 0.1264 
 3 0.0180 
 4 0.0010 
Severe
c
 
  
 0 0.4251 
 1 0.4054 
 2 0.1450 
 3 0.0230 
 4 0.0014 
a. Exacerbation frequency (per annum) = 0.79 
b. Exacerbation frequency (per annum) = 1.22 
c. Exacerbation frequency (per annum) = 1.47  
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Table D.3: Probability tables for minor COPD exacerbation 
Mild COPD
a
  Moderate COPD
b
  Severe COPD
c
 
n x f(x,p,n)  n x f(x,p,n)  n x f(x,p,n) 
4 
  
 4    4   
 0 0.0000   0 0.0000   0 0.0001 
 1 0.0008   1 0.0013   1 0.0036 
 2 0.0191   2 0.0254   2 0.0486 
 3 0.1993   3 0.2252   3 0.2916 
 4 0.7807   4 0.7481   4 0.6561 
3 
  
 3    3   
 0 0.0002   0 0.0003   0 0.0010 
 1 0.0102   1 0.0137   1 0.0270 
 2 0.1590   2 0.1816   2 0.2430 
 3 0.8306   3 0.8044   3 0.7290 
2 
  
 2    2   
 0 0.0036   0 0.0049   0 0.0100 
 1 0.1128   1 0.1302   1 0.1800 
 2 0.8836   2 0.8649   2 0.8100 
1 
  
 1    1   
 0 0.0600   0 0.0700   0 0.1000 
 1 0.9400   1 0.9300   1 0.9000 
a. P(minor exacerbation | COPD exacerbation event) = 0.94 
b. P(minor exacerbation | COPD exacerbation event) = 0.93 
c. P(minor exacerbation | COPD exacerbation event) = 0.90 
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